HRP20130155T1 - Fuzionirani heterocikliäśki spojevi korisni kao modulatori kinaze - Google Patents
Fuzionirani heterocikliäśki spojevi korisni kao modulatori kinaze Download PDFInfo
- Publication number
- HRP20130155T1 HRP20130155T1 HRP20130155TT HRP20130155T HRP20130155T1 HR P20130155 T1 HRP20130155 T1 HR P20130155T1 HR P20130155T T HRP20130155T T HR P20130155TT HR P20130155 T HRP20130155 T HR P20130155T HR P20130155 T1 HRP20130155 T1 HR P20130155T1
- Authority
- HR
- Croatia
- Prior art keywords
- aminocyclohexyl
- trans
- imidazo
- pyridazine
- diamine
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000001072 heteroaryl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical group 0.000 claims 20
- -1 heterocyclo Chemical group 0.000 claims 19
- 150000002431 hydrogen Chemical group 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- 125000000547 substituted alkyl group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000006413 ring segment Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- RBRRHFVIWGJKTL-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2F)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2F)F)=C1 RBRRHFVIWGJKTL-HAQNSBGRSA-N 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 229910006069 SO3H Inorganic materials 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 3
- OMWMIYWQRVOUME-UHFFFAOYSA-N 6-(3-aminopiperidin-1-yl)-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CC(N)CCC2)=NN2C1=NC=C2 OMWMIYWQRVOUME-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- OEVMIPJEUGOVPG-JCNLHEQBSA-N C1=CC(OCC)=CC=C1NC1=C(CC)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(CC)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 OEVMIPJEUGOVPG-JCNLHEQBSA-N 0.000 claims 2
- LDKODFQIGKBEIB-CTYIDZIISA-N C1=CC(OCC)=CC=C1NC1=C(Cl)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(Cl)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 LDKODFQIGKBEIB-CTYIDZIISA-N 0.000 claims 2
- TYEWIQQSOVFEQB-AQYVVDRMSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C(N(C=4C=CC(F)=CC=4)C=CC=3)=O)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C(N(C=4C=CC(F)=CC=4)C=CC=3)=O)=CC=2)=C1 TYEWIQQSOVFEQB-AQYVVDRMSA-N 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- RPGYXCOFUUNHFA-KOMQPUFPSA-N N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(CC)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(CC)C=1N[C@H]1CC[C@H](N)CC1 RPGYXCOFUUNHFA-KOMQPUFPSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- ZWBFLQKNWXAVDT-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound N1=C(N)C=C(N)C2=NC=CN21 ZWBFLQKNWXAVDT-UHFFFAOYSA-N 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- RRXPOLXIYLTJJF-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[4-(imidazo[1,2-b]pyridazin-8-ylamino)phenyl]-2-oxopiperidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NC=2C=CC(NC=3C4=NC=CN4N=CC=3)=CC=2)CCC1 RRXPOLXIYLTJJF-UHFFFAOYSA-N 0.000 claims 1
- NCDDUQLSGLCJJI-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[4-(imidazo[1,2-b]pyridazin-8-ylamino)phenyl]-2-oxopyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NC=2C=CC(NC=3C4=NC=CN4N=CC=3)=CC=2)=CC=C1 NCDDUQLSGLCJJI-UHFFFAOYSA-N 0.000 claims 1
- XKNAGLMNQADBQE-UHFFFAOYSA-N 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical group O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(OC=3C=CN=CC=3)=CC=2)=N1 XKNAGLMNQADBQE-UHFFFAOYSA-N 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- CZYTUNVGDISHLR-UHFFFAOYSA-N 2-[1-[8-(4-ethoxyanilino)imidazo[1,2-b]pyridazin-6-yl]piperidin-4-yl]ethanol Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CCC(CCO)CC2)=NN2C1=NC=C2 CZYTUNVGDISHLR-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- VPXNBUFYFHEGML-UHFFFAOYSA-N 4-[[6-[(4-aminocyclohexyl)amino]-7-methylimidazo[1,2-b]pyridazin-8-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=C(C)C(NC2CCC(N)CC2)=NN2C1=NC=C2 VPXNBUFYFHEGML-UHFFFAOYSA-N 0.000 claims 1
- IYMHHVRRYYJNOK-UHFFFAOYSA-N 6-(3-aminopyrrolidin-1-yl)-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CC(N)CC2)=NN2C1=NC=C2 IYMHHVRRYYJNOK-UHFFFAOYSA-N 0.000 claims 1
- IYMHHVRRYYJNOK-ZDUSSCGKSA-N 6-[(3s)-3-aminopyrrolidin-1-yl]-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2C[C@@H](N)CC2)=NN2C1=NC=C2 IYMHHVRRYYJNOK-ZDUSSCGKSA-N 0.000 claims 1
- NKOGROICVHNSME-UHFFFAOYSA-N 6-n-(1-amino-4-bicyclo[2.2.2]octanyl)-8-n-phenylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1CC(N)(CC2)CCC12NC(=NN1C=CN=C11)C=C1NC1=CC=CC=C1 NKOGROICVHNSME-UHFFFAOYSA-N 0.000 claims 1
- CVVYVGWYNYFRTA-UHFFFAOYSA-N 6-n-(2-aminoethyl)-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NCCN)=NN2C1=NC=C2 CVVYVGWYNYFRTA-UHFFFAOYSA-N 0.000 claims 1
- BRSIKYRISNDSKK-UHFFFAOYSA-N 6-n-(3-aminocyclopentyl)-8-n-phenylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1C(N)CCC1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 BRSIKYRISNDSKK-UHFFFAOYSA-N 0.000 claims 1
- HMMOKPMWQOHXQC-UHFFFAOYSA-N 6-n-(3-aminopropyl)-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NCCCN)=NN2C1=NC=C2 HMMOKPMWQOHXQC-UHFFFAOYSA-N 0.000 claims 1
- BTRYRXKUZCBZHK-UHFFFAOYSA-N 6-n-(4-aminobutyl)-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NCCCCN)=NN2C1=NC=C2 BTRYRXKUZCBZHK-UHFFFAOYSA-N 0.000 claims 1
- XXTXMMMMXWVDHF-UHFFFAOYSA-N 6-n-(4-aminocyclohexyl)-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NC2CCC(N)CC2)=NN2C1=NC=C2 XXTXMMMMXWVDHF-UHFFFAOYSA-N 0.000 claims 1
- DERWYMXCWNCKHW-UHFFFAOYSA-N 6-n-[2-(dimethylamino)ethyl]-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NCCN(C)C)=NN2C1=NC=C2 DERWYMXCWNCKHW-UHFFFAOYSA-N 0.000 claims 1
- UAYWPNWVHGVOLN-UHFFFAOYSA-N 6-n-[4-[(4-aminocyclohexyl)methyl]cyclohexyl]-8-n-(4-ethoxyphenyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NC2CCC(CC3CCC(N)CC3)CC2)=NN2C1=NC=C2 UAYWPNWVHGVOLN-UHFFFAOYSA-N 0.000 claims 1
- UQLOIYALTVZLPF-UHFFFAOYSA-N 7-chloro-n-(4-ethoxyphenyl)-6-piperazin-1-ylimidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=C(Cl)C(N2CCNCC2)=NN2C1=NC=C2 UQLOIYALTVZLPF-UHFFFAOYSA-N 0.000 claims 1
- BUBOWIYZSCCPFG-UHFFFAOYSA-N 8-n-(4-ethoxyphenyl)-6-n-(furan-2-ylmethyl)imidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NCC=2OC=CC=2)=NN2C1=NC=C2 BUBOWIYZSCCPFG-UHFFFAOYSA-N 0.000 claims 1
- PCDZINPUIMLKAY-UHFFFAOYSA-N 8-n-(4-ethoxyphenyl)-6-n-piperidin-3-ylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NC2CNCCC2)=NN2C1=NC=C2 PCDZINPUIMLKAY-UHFFFAOYSA-N 0.000 claims 1
- RAFXBLJMTASJGI-UHFFFAOYSA-N 8-n-(4-ethoxyphenyl)-6-n-piperidin-4-ylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NC2CCNCC2)=NN2C1=NC=C2 RAFXBLJMTASJGI-UHFFFAOYSA-N 0.000 claims 1
- SJNRRFPMBRVCNV-UHFFFAOYSA-N 8-n-(4-ethoxyphenyl)-6-n-pyrrolidin-3-ylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(NC2CNCC2)=NN2C1=NC=C2 SJNRRFPMBRVCNV-UHFFFAOYSA-N 0.000 claims 1
- KBRXCPITUPTVLJ-UHFFFAOYSA-N 8-n-(4-ethoxyphenyl)-7-methyl-6-n-piperidin-3-ylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1=CC(OCC)=CC=C1NC1=C(C)C(NC2CNCCC2)=NN2C1=NC=C2 KBRXCPITUPTVLJ-UHFFFAOYSA-N 0.000 claims 1
- UEJUJNWHYDMWFC-UHFFFAOYSA-N 8-n-phenyl-6-n-piperidin-3-ylimidazo[1,2-b]pyridazine-6,8-diamine Chemical compound C1CCNCC1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 UEJUJNWHYDMWFC-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000004429 Bacillary Dysentery Diseases 0.000 claims 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims 1
- XSYAJDWENLIOBH-HDJSIYSDSA-N C1=C(C(F)(F)F)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XSYAJDWENLIOBH-HDJSIYSDSA-N 0.000 claims 1
- KSCKWRKAPPOJEJ-QAQDUYKDSA-N C1=C(C)C(C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(C)C(C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 KSCKWRKAPPOJEJ-QAQDUYKDSA-N 0.000 claims 1
- JLLQYGJTWOMHBW-WKILWMFISA-N C1=C(C)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(C)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JLLQYGJTWOMHBW-WKILWMFISA-N 0.000 claims 1
- JLLQYGJTWOMHBW-IYBDPMFKSA-N C1=C(C)C(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(C)C(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JLLQYGJTWOMHBW-IYBDPMFKSA-N 0.000 claims 1
- GBXZEPVASCWLDS-HDJSIYSDSA-N C1=C(Cl)C(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound C1=C(Cl)C(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 GBXZEPVASCWLDS-HDJSIYSDSA-N 0.000 claims 1
- FATFTTHBDDSNDJ-HDJSIYSDSA-N C1=C(F)C(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound C1=C(F)C(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 FATFTTHBDDSNDJ-HDJSIYSDSA-N 0.000 claims 1
- HSOZZMPWVCGTMW-HDJSIYSDSA-N C1=C(F)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(F)C(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 HSOZZMPWVCGTMW-HDJSIYSDSA-N 0.000 claims 1
- MVDBIBQEHMDKGF-HDJSIYSDSA-N C1=C(O)C(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(O)C(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 MVDBIBQEHMDKGF-HDJSIYSDSA-N 0.000 claims 1
- XKBISLWPXVERFJ-HDJSIYSDSA-N C1=C(OC)C(OC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=C(OC)C(OC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XKBISLWPXVERFJ-HDJSIYSDSA-N 0.000 claims 1
- ZUXHFLKYVGSDMW-HDJSIYSDSA-N C1=C2SC(C)=NC2=CC=C1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound C1=C2SC(C)=NC2=CC=C1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 ZUXHFLKYVGSDMW-HDJSIYSDSA-N 0.000 claims 1
- QUKAAEYQRASRQK-JCNLHEQBSA-N C1=CC(C(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 QUKAAEYQRASRQK-JCNLHEQBSA-N 0.000 claims 1
- FWNWBUROLRVIBF-UAPYVXQJSA-N C1=CC(C(=O)N(CC)CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 FWNWBUROLRVIBF-UAPYVXQJSA-N 0.000 claims 1
- ZAMJARIQWGZYAS-SAABIXHNSA-N C1=CC(C(C)(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C(C)(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 ZAMJARIQWGZYAS-SAABIXHNSA-N 0.000 claims 1
- ZHOQRBULLCKLQG-SAABIXHNSA-N C1=CC(C(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 ZHOQRBULLCKLQG-SAABIXHNSA-N 0.000 claims 1
- JAVWLIUBCWHDLX-AQYVVDRMSA-N C1=CC(C)=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C)=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JAVWLIUBCWHDLX-AQYVVDRMSA-N 0.000 claims 1
- SGBOMRBWELDYBD-JCNLHEQBSA-N C1=CC(C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 SGBOMRBWELDYBD-JCNLHEQBSA-N 0.000 claims 1
- XNNPKSXNMNZWBM-KOMQPUFPSA-N C1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XNNPKSXNMNZWBM-KOMQPUFPSA-N 0.000 claims 1
- XNNPKSXNMNZWBM-FZNQNYSPSA-N C1=CC(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XNNPKSXNMNZWBM-FZNQNYSPSA-N 0.000 claims 1
- AASYUONHKUEHMU-JCNLHEQBSA-N C1=CC(CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 AASYUONHKUEHMU-JCNLHEQBSA-N 0.000 claims 1
- JKRSWJDHWKRRLX-SAABIXHNSA-N C1=CC(CCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(CCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JKRSWJDHWKRRLX-SAABIXHNSA-N 0.000 claims 1
- YBQSRTQSPFUJCF-UAPYVXQJSA-N C1=CC(CCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(CCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 YBQSRTQSPFUJCF-UAPYVXQJSA-N 0.000 claims 1
- QRINITWHHBHOAW-KOMQPUFPSA-N C1=CC(CN)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(CN)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 QRINITWHHBHOAW-KOMQPUFPSA-N 0.000 claims 1
- WKTJPXUNRVAJMV-SAABIXHNSA-N C1=CC(N(C(C)=O)C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(N(C(C)=O)C)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 WKTJPXUNRVAJMV-SAABIXHNSA-N 0.000 claims 1
- UGFKCXAJYGGZGQ-CZIWCDLHSA-N C1=CC(NC(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 UGFKCXAJYGGZGQ-CZIWCDLHSA-N 0.000 claims 1
- GCLLKMQUUBAPQB-CTYIDZIISA-N C1=CC(NS(=O)(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 GCLLKMQUUBAPQB-CTYIDZIISA-N 0.000 claims 1
- SJKTXBARMLKRGG-JCNLHEQBSA-N C1=CC(OC(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OC(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 SJKTXBARMLKRGG-JCNLHEQBSA-N 0.000 claims 1
- YWLQTGSNAJDOHN-QAQDUYKDSA-N C1=CC(OC)=CC=C1CCNC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OC)=CC=C1CCNC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 YWLQTGSNAJDOHN-QAQDUYKDSA-N 0.000 claims 1
- JHAQBAPRPUKXKI-WKILWMFISA-N C1=CC(OC)=CC=C1CNC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OC)=CC=C1CNC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JHAQBAPRPUKXKI-WKILWMFISA-N 0.000 claims 1
- XMLXYCAQOHCJED-CTYIDZIISA-N C1=CC(OC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XMLXYCAQOHCJED-CTYIDZIISA-N 0.000 claims 1
- RMUZPTMNFPGKCI-JCNLHEQBSA-N C1=CC(OCC)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 RMUZPTMNFPGKCI-JCNLHEQBSA-N 0.000 claims 1
- RMUZPTMNFPGKCI-WOVMCDHWSA-N C1=CC(OCC)=CC=C1NC1=C(C)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(C)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 RMUZPTMNFPGKCI-WOVMCDHWSA-N 0.000 claims 1
- NYUJKJCBLPUGLY-XUTJKUGGSA-N C1=CC(OCC)=CC=C1NC1=C(C=2C=CC=CC=2)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(C=2C=CC=CC=2)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 NYUJKJCBLPUGLY-XUTJKUGGSA-N 0.000 claims 1
- NYUJKJCBLPUGLY-TYKWCNGQSA-N C1=CC(OCC)=CC=C1NC1=C(C=2C=CC=CC=2)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=C(C=2C=CC=CC=2)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 NYUJKJCBLPUGLY-TYKWCNGQSA-N 0.000 claims 1
- OKNFAHPWKCLHMS-SAABIXHNSA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC(C)=C2C Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC(C)=C2C OKNFAHPWKCLHMS-SAABIXHNSA-N 0.000 claims 1
- AASNUYSDEFQDSV-JCNLHEQBSA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C AASNUYSDEFQDSV-JCNLHEQBSA-N 0.000 claims 1
- PDEFJRDSURAZNG-KOMQPUFPSA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C#N Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2C#N PDEFJRDSURAZNG-KOMQPUFPSA-N 0.000 claims 1
- SKFKKJOFJMGKHM-CTYIDZIISA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2F Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2F SKFKKJOFJMGKHM-CTYIDZIISA-N 0.000 claims 1
- XXTXMMMMXWVDHF-FZNQNYSPSA-N C1=CC(OCC)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 XXTXMMMMXWVDHF-FZNQNYSPSA-N 0.000 claims 1
- ZPYGLDOKYJQXPH-SAABIXHNSA-N C1=CC(OCCC)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCCC)=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 ZPYGLDOKYJQXPH-SAABIXHNSA-N 0.000 claims 1
- ZWYBIYDAYUYXTJ-JCNLHEQBSA-N C1=CC(OCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 ZWYBIYDAYUYXTJ-JCNLHEQBSA-N 0.000 claims 1
- JVZMLXGPTQYXEX-SAABIXHNSA-N C1=CC(OCCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(OCCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 JVZMLXGPTQYXEX-SAABIXHNSA-N 0.000 claims 1
- HBJLBRUEPVJVMT-FZNQNYSPSA-N C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 HBJLBRUEPVJVMT-FZNQNYSPSA-N 0.000 claims 1
- NGOXSCLNXQYQBC-SAABIXHNSA-N C1=CC(S(=O)(=O)N(CC)CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 NGOXSCLNXQYQBC-SAABIXHNSA-N 0.000 claims 1
- GMKWUAXBOOWKQY-CTYIDZIISA-N C1=CC(S(=O)(=O)NC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 GMKWUAXBOOWKQY-CTYIDZIISA-N 0.000 claims 1
- DRJSKBUBRZZIMD-KOMQPUFPSA-N C1=CC(S(=O)(=O)NCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 DRJSKBUBRZZIMD-KOMQPUFPSA-N 0.000 claims 1
- QYDKHWOLAUZKDL-JCNLHEQBSA-N C1=CC(S(=O)(=O)NCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(S(=O)(=O)NCCC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 QYDKHWOLAUZKDL-JCNLHEQBSA-N 0.000 claims 1
- AOKFXBKLPBIHLH-CTYIDZIISA-N C1=CC(SC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1=CC(SC)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 AOKFXBKLPBIHLH-CTYIDZIISA-N 0.000 claims 1
- IPKKZSZQSXRDAR-HDJSIYSDSA-N C1=NC(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound C1=NC(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 IPKKZSZQSXRDAR-HDJSIYSDSA-N 0.000 claims 1
- FZWRZTVZNPFAJK-MTNLDAPISA-N C1C(N(C)C)CCN1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound C1C(N(C)C)CCN1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 FZWRZTVZNPFAJK-MTNLDAPISA-N 0.000 claims 1
- IMZWNAMEVWZZHQ-IYARVYRRSA-N C1CCC2=CC(C)=CC=C2N1C(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound C1CCC2=CC(C)=CC=C2N1C(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 IMZWNAMEVWZZHQ-IYARVYRRSA-N 0.000 claims 1
- KKQGFRSBPBCYHJ-KESTWPANSA-N C1C[C@@H](N)CC[C@@H]1NC(C(=C1NC=2C=CC=CC=2)C=2C=CC=CC=2)=NN2C1=NC=C2 Chemical compound C1C[C@@H](N)CC[C@@H]1NC(C(=C1NC=2C=CC=CC=2)C=2C=CC=CC=2)=NN2C1=NC=C2 KKQGFRSBPBCYHJ-KESTWPANSA-N 0.000 claims 1
- VJIPYULVLXMZOC-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 VJIPYULVLXMZOC-CTYIDZIISA-N 0.000 claims 1
- ISLYOFBOHHGXPK-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C(N)=O)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C(C(N)=O)=CN=C2C(NC=2C=CC=CC=2)=C1 ISLYOFBOHHGXPK-MQMHXKEQSA-N 0.000 claims 1
- FWYXJOIUGUBHDN-KYZUINATSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(N)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(N)=C1 FWYXJOIUGUBHDN-KYZUINATSA-N 0.000 claims 1
- IEOYOODRCOAEMG-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)C=2C=CC=CC=2)=C1 IEOYOODRCOAEMG-SHTZXODSSA-N 0.000 claims 1
- MDDIJEDLJOBHEY-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC(=O)NC=2C=CC=CC=2)=C1 MDDIJEDLJOBHEY-CTYIDZIISA-N 0.000 claims 1
- LMRMBXOLSOECQC-XYPYZODXSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2=NNC=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2=NNC=C2)=C1 LMRMBXOLSOECQC-XYPYZODXSA-N 0.000 claims 1
- RNFDNJVZUHUIMY-UMSPYCQHSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2CC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2CC2)=C1 RNFDNJVZUHUIMY-UMSPYCQHSA-N 0.000 claims 1
- SCHNKMHWASZDKJ-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC2CCCCC2)=C1 SCHNKMHWASZDKJ-CTYIDZIISA-N 0.000 claims 1
- KEPTXXHEZILHKA-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=C(F)C=CC=2)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=C(F)C=CC=2)F)=C1 KEPTXXHEZILHKA-HAQNSBGRSA-N 0.000 claims 1
- IMBGPZXQRKWMFM-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC(Cl)=CC=2)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC(Cl)=CC=2)F)=C1 IMBGPZXQRKWMFM-JOCQHMNTSA-N 0.000 claims 1
- POLDXHUNVORPIK-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC(F)=CC=2)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC(F)=CC=2)F)=C1 POLDXHUNVORPIK-JOCQHMNTSA-N 0.000 claims 1
- MVEVEYKWHGOUAB-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=C(F)C=2)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=C(F)C=2)F)=C1 MVEVEYKWHGOUAB-JOCQHMNTSA-N 0.000 claims 1
- IVUDFDOJYSOTRH-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)Cl)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)Cl)=C1 IVUDFDOJYSOTRH-JOCQHMNTSA-N 0.000 claims 1
- VQFMBPMHDBSMTN-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)F)=C1 VQFMBPMHDBSMTN-JOCQHMNTSA-N 0.000 claims 1
- ZSFRWNNKBMIOOC-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)O)=C1 ZSFRWNNKBMIOOC-JOCQHMNTSA-N 0.000 claims 1
- NBFNOXGMHUWQBW-IYARVYRRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1 NBFNOXGMHUWQBW-IYARVYRRSA-N 0.000 claims 1
- FCRDZAPKMOOQTE-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C3=CC=CC=C3C(Cl)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C3=CC=CC=C3C(Cl)=CC=2)=C1 FCRDZAPKMOOQTE-SHTZXODSSA-N 0.000 claims 1
- XSQAMMZOLAFCTR-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C3=CC=CC=C3C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C3=CC=CC=C3C=CC=2)=C1 XSQAMMZOLAFCTR-QAQDUYKDSA-N 0.000 claims 1
- ZDVKKWFUMAIPGN-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=3CCCCC=3C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=3CCCCC=3C=CC=2)=C1 ZDVKKWFUMAIPGN-QAQDUYKDSA-N 0.000 claims 1
- ADXLFHFPANLMRH-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C#N)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C#N)=C1 ADXLFHFPANLMRH-SHTZXODSSA-N 0.000 claims 1
- BDONQTAZVMDUST-KESTWPANSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=C1 BDONQTAZVMDUST-KESTWPANSA-N 0.000 claims 1
- OPJYSSBKRQXKAB-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(F)(F)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(F)(F)F)=C1 OPJYSSBKRQXKAB-HDJSIYSDSA-N 0.000 claims 1
- XIPWTNKXXMNNRB-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(N)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(N)=O)=C1 XIPWTNKXXMNNRB-HDJSIYSDSA-N 0.000 claims 1
- INILGZLACGMTIF-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C(O)=O)=C1 INILGZLACGMTIF-HDJSIYSDSA-N 0.000 claims 1
- JORNKTFMVWKAOE-MXVIHJGJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C=2C=C(Cl)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C=2C=C(Cl)C=CC=2)=C1 JORNKTFMVWKAOE-MXVIHJGJSA-N 0.000 claims 1
- BJAZMPWMWGRAHI-MXVIHJGJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 BJAZMPWMWGRAHI-MXVIHJGJSA-N 0.000 claims 1
- XJVAFPYNDDFYBE-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)S(=O)(=O)N2CCOCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)S(=O)(=O)N2CCOCC2)=C1 XJVAFPYNDDFYBE-QAQDUYKDSA-N 0.000 claims 1
- UKPXRNPRCSXRAQ-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)S(N)(=O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(C=CC=2)S(N)(=O)=O)=C1 UKPXRNPRCSXRAQ-JOCQHMNTSA-N 0.000 claims 1
- LATDGTUFCBADDH-MEMLXQNLSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(CC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(CC=3C=CC=CC=3)C=CC=2)=C1 LATDGTUFCBADDH-MEMLXQNLSA-N 0.000 claims 1
- MOMLZCZAXZDJBB-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(Cl)C=C(Cl)C=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(Cl)C=C(Cl)C=2)=C1 MOMLZCZAXZDJBB-HDJSIYSDSA-N 0.000 claims 1
- PVURRJWCULAUCZ-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(Cl)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(Cl)C=CC=2)=C1 PVURRJWCULAUCZ-HDJSIYSDSA-N 0.000 claims 1
- SIMCOQZRZPZWDB-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C(F)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C(F)=CC=2)=C1 SIMCOQZRZPZWDB-HAQNSBGRSA-N 0.000 claims 1
- UCKSIIIANHXUCG-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C=C(F)C=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C=C(F)C=2)=C1 UCKSIIIANHXUCG-HDJSIYSDSA-N 0.000 claims 1
- BZKOMHUEQJFYFY-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(F)C=CC=2)=C1 BZKOMHUEQJFYFY-HDJSIYSDSA-N 0.000 claims 1
- NPFNBHHKFHLFKM-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(I)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(I)C=CC=2)=C1 NPFNBHHKFHLFKM-HDJSIYSDSA-N 0.000 claims 1
- BIUNZHGGBJCAFD-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(O)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(O)C=CC=2)=C1 BIUNZHGGBJCAFD-JOCQHMNTSA-N 0.000 claims 1
- LINCBACXBWTOQN-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OC(F)(F)F)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OC(F)(F)F)C=CC=2)=C1 LINCBACXBWTOQN-JOCQHMNTSA-N 0.000 claims 1
- HBGTWIKBHVOZOW-IYARVYRRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OC=3C=CC=CC=3)C=CC=2)=C1 HBGTWIKBHVOZOW-IYARVYRRSA-N 0.000 claims 1
- NXXOTSORPSEGFY-MXVIHJGJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=C1 NXXOTSORPSEGFY-MXVIHJGJSA-N 0.000 claims 1
- WNTXSFQCBNVJHJ-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C(C(NN3)=O)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C(C(NN3)=O)=CC=2)=C1 WNTXSFQCBNVJHJ-HAQNSBGRSA-N 0.000 claims 1
- ASGWUXYZOVGBMV-WGSAOQKQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C(C4=CC=CC=C4C3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C(C4=CC=CC=C4C3)=CC=2)=C1 ASGWUXYZOVGBMV-WGSAOQKQSA-N 0.000 claims 1
- KCDMLVHAFXQQBV-IYARVYRRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CC=CC3=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CC=CC3=CC=2)=C1 KCDMLVHAFXQQBV-IYARVYRRSA-N 0.000 claims 1
- RJQVUIDHUYBLRT-WKILWMFISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CC=CC3=NC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CC=CC3=NC=2)=C1 RJQVUIDHUYBLRT-WKILWMFISA-N 0.000 claims 1
- BKEHFODMSVAMFK-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CNC3=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3C=CNC3=CC=2)=C1 BKEHFODMSVAMFK-SHTZXODSSA-N 0.000 claims 1
- NWWUSNNJRQFGFK-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3CCCC3=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=C3CCCC3=CC=2)=C1 NWWUSNNJRQFGFK-QAQDUYKDSA-N 0.000 claims 1
- FVKAFOLBMYXPDE-KOMQPUFPSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C#N)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C#N)=C1 FVKAFOLBMYXPDE-KOMQPUFPSA-N 0.000 claims 1
- DBFMVPPCXSBHAT-JKBWNCLQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CC(CC2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CC(CC2)C=2C=CC=CC=2)=C1 DBFMVPPCXSBHAT-JKBWNCLQSA-N 0.000 claims 1
- PIBCSILAVMMGAR-YOCNBXQISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCC(CC2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCC(CC2)C=2C=CC=CC=2)=C1 PIBCSILAVMMGAR-YOCNBXQISA-N 0.000 claims 1
- MFQNTPIGWOOXCO-UAPYVXQJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCCC2)=C1 MFQNTPIGWOOXCO-UAPYVXQJSA-N 0.000 claims 1
- JTOPHZLKQIMQOV-KESTWPANSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCCCC2)=C1 JTOPHZLKQIMQOV-KESTWPANSA-N 0.000 claims 1
- AWBMLQSHYRYXRK-UAPYVXQJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCOCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCOCC2)=C1 AWBMLQSHYRYXRK-UAPYVXQJSA-N 0.000 claims 1
- YVKBJIQOGDHJFK-JCNLHEQBSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC2CC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC2CC2)=C1 YVKBJIQOGDHJFK-JCNLHEQBSA-N 0.000 claims 1
- OTQZKRUKKZZWHM-XGAFWQRZSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC2CCCCC2)=C1 OTQZKRUKKZZWHM-XGAFWQRZSA-N 0.000 claims 1
- UBQPRXGVWKHHBF-AFARHQOCSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C(N(C=3C=CC(F)=CC=3)C=CC=2)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C(N(C=3C=CC(F)=CC=3)C=CC=2)=O)=C1 UBQPRXGVWKHHBF-AFARHQOCSA-N 0.000 claims 1
- CSYCDTJUIFWHKD-XGAFWQRZSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C=CC=CC=2)=C1 CSYCDTJUIFWHKD-XGAFWQRZSA-N 0.000 claims 1
- RMABXBZIZGPZPV-UAPYVXQJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C=NC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NC=2C=NC=CC=2)=C1 RMABXBZIZGPZPV-UAPYVXQJSA-N 0.000 claims 1
- BNKZEOZEYRCPSL-AQYVVDRMSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC2CCCCC2)=C1 BNKZEOZEYRCPSL-AQYVVDRMSA-N 0.000 claims 1
- KDFNYZYCTMTQQP-AQYVVDRMSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=CC=CC=2)=C1 KDFNYZYCTMTQQP-AQYVVDRMSA-N 0.000 claims 1
- UIOCXPFLPODTAS-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=CN=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=CN=CC=2)=C1 UIOCXPFLPODTAS-XUTJKUGGSA-N 0.000 claims 1
- SQXUYQCEBQZALX-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=NC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2C=NC=CC=2)=C1 SQXUYQCEBQZALX-XUTJKUGGSA-N 0.000 claims 1
- JYGJFJJZVTXXEP-SAABIXHNSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2N=CNC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2N=CNC=2)=C1 JYGJFJJZVTXXEP-SAABIXHNSA-N 0.000 claims 1
- KZWDNNLEYKNNRR-UAPYVXQJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2OC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCC=2OC=CC=2)=C1 KZWDNNLEYKNNRR-UAPYVXQJSA-N 0.000 claims 1
- PGCQNOJBDPKEAG-AQYVVDRMSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCC=2C=CN=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCC=2C=CN=CC=2)=C1 PGCQNOJBDPKEAG-AQYVVDRMSA-N 0.000 claims 1
- VSCGAIHGOBUCOG-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCCN2C(CCC2)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCCN2C(CCC2)=O)=C1 VSCGAIHGOBUCOG-XUTJKUGGSA-N 0.000 claims 1
- QMHYORCCZMZOOR-JCNLHEQBSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCO)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)NCCO)=C1 QMHYORCCZMZOOR-JCNLHEQBSA-N 0.000 claims 1
- IFZLYHHMWASNDF-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(F)(F)F)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(F)(F)F)=C1 IFZLYHHMWASNDF-CTYIDZIISA-N 0.000 claims 1
- BWQPENDIBAOXPY-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(N)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(N)=O)=C1 BWQPENDIBAOXPY-CTYIDZIISA-N 0.000 claims 1
- BFRUMZZTBHOIAP-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C1 BFRUMZZTBHOIAP-CTYIDZIISA-N 0.000 claims 1
- LHNAIQZWXQZTFN-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C2CCCCC2)=C1 LHNAIQZWXQZTFN-XUTJKUGGSA-N 0.000 claims 1
- RMRQTGYVGMRSTN-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=C(Cl)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=C(Cl)C=CC=2)=C1 RMRQTGYVGMRSTN-XUTJKUGGSA-N 0.000 claims 1
- LLZZSYPJPZAKOC-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 LLZZSYPJPZAKOC-XUTJKUGGSA-N 0.000 claims 1
- RTLQERLZCSYPCF-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 RTLQERLZCSYPCF-XUTJKUGGSA-N 0.000 claims 1
- UVLUGFMNLJHDJT-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2NN=NN=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C=2NN=NN=2)=C1 UVLUGFMNLJHDJT-CTYIDZIISA-N 0.000 claims 1
- IESSVGVEPLXBRN-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C(=C(Cl)N=C2)Cl)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C(=C(Cl)N=C2)Cl)=C1 IESSVGVEPLXBRN-CTYIDZIISA-N 0.000 claims 1
- VBBKNMJQNGUJQN-SAABIXHNSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C=CC=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C=CC=C2)=C1 VBBKNMJQNGUJQN-SAABIXHNSA-N 0.000 claims 1
- RFUUNESIGIVYRO-JCNLHEQBSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C=NC=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2C=NC=C2)=C1 RFUUNESIGIVYRO-JCNLHEQBSA-N 0.000 claims 1
- IMMCFOOCHHOGHL-SAABIXHNSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2CCOCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2CCOCC2)=C1 IMMCFOOCHHOGHL-SAABIXHNSA-N 0.000 claims 1
- FEGXYXPSNFYCNO-JCNLHEQBSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CC=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CC=C2)=C1 FEGXYXPSNFYCNO-JCNLHEQBSA-N 0.000 claims 1
- DHIFVUDOIIMCPS-KOMQPUFPSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CN=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CN=C2)=C1 DHIFVUDOIIMCPS-KOMQPUFPSA-N 0.000 claims 1
- JQEHPCNPNPZRJB-SAABIXHNSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(=O)(=O)N2CCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(=O)(=O)N2CCCC2)=C1 JQEHPCNPNPZRJB-SAABIXHNSA-N 0.000 claims 1
- BPWNZKVHZDLQJQ-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(N)(=O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(N)(=O)=O)=C1 BPWNZKVHZDLQJQ-MQMHXKEQSA-N 0.000 claims 1
- HQFSOLPHORNRIV-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(O)(=O)=O)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)S(O)(=O)=O)=C1 HQFSOLPHORNRIV-MQMHXKEQSA-N 0.000 claims 1
- CASPQNOIPLLWBP-AQYVVDRMSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 CASPQNOIPLLWBP-AQYVVDRMSA-N 0.000 claims 1
- PQKOSOIDVAXLHQ-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(Cl)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(Cl)=CC=2)=C1 PQKOSOIDVAXLHQ-CTYIDZIISA-N 0.000 claims 1
- VPQUVFJDJUYUDG-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(F)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(F)=CC=2)=C1 VPQUVFJDJUYUDG-CTYIDZIISA-N 0.000 claims 1
- DCSCXGXFCGTVSO-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(N)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(N)=CC=2)=C1 DCSCXGXFCGTVSO-CTYIDZIISA-N 0.000 claims 1
- MPBKGMFEWBLBKS-KESTWPANSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)C=3C=CC=CC=3)=CC=2)=C1 MPBKGMFEWBLBKS-KESTWPANSA-N 0.000 claims 1
- PCUTWNIUUUWMIF-IRJFHVNHSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C1 PCUTWNIUUUWMIF-IRJFHVNHSA-N 0.000 claims 1
- QUQLQIANWFAGOL-MQMHXKEQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(O)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(O)=CC=2)=C1 QUQLQIANWFAGOL-MQMHXKEQSA-N 0.000 claims 1
- REQDKWXWLVCPGD-UAPYVXQJSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 REQDKWXWLVCPGD-UAPYVXQJSA-N 0.000 claims 1
- QYJAGOBLXUEIDF-XUTJKUGGSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 QYJAGOBLXUEIDF-XUTJKUGGSA-N 0.000 claims 1
- QITHNUYCWSICAW-CTYIDZIISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 QITHNUYCWSICAW-CTYIDZIISA-N 0.000 claims 1
- UPHGSDWIKSRMHS-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=NC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=NC=CC=2)=C1 UPHGSDWIKSRMHS-JOCQHMNTSA-N 0.000 claims 1
- CQIFMGQAAVSDME-WGSAOQKQSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 CQIFMGQAAVSDME-WGSAOQKQSA-N 0.000 claims 1
- RUKFWRUSRWZENX-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC=CC=2)=C1 RUKFWRUSRWZENX-JOCQHMNTSA-N 0.000 claims 1
- HWOPEKBHKXEAQT-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC=CN=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2N=CC=CN=2)=C1 HWOPEKBHKXEAQT-HAQNSBGRSA-N 0.000 claims 1
- VVNBAUCJIGNPPQ-JOCQHMNTSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC2CC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC2CC2)=C1 VVNBAUCJIGNPPQ-JOCQHMNTSA-N 0.000 claims 1
- VITCEAWABUDQKM-WKILWMFISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC2CCCCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC2CCCCC2)=C1 VITCEAWABUDQKM-WKILWMFISA-N 0.000 claims 1
- ZVRQJLRGGYTJLG-SHTZXODSSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C(=CC=CC=2)Cl)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C(=CC=CC=2)Cl)=C1 ZVRQJLRGGYTJLG-SHTZXODSSA-N 0.000 claims 1
- HNWOEXDOZNNSGR-WKILWMFISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=C(Cl)C=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=C(Cl)C=CC=2)=C1 HNWOEXDOZNNSGR-WKILWMFISA-N 0.000 claims 1
- SQRNDKILDSVIPN-WKILWMFISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=CC(Cl)=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=CC(Cl)=CC=2)=C1 SQRNDKILDSVIPN-WKILWMFISA-N 0.000 claims 1
- OZLJCVCREYSDSH-WKILWMFISA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=2C=CC=CC=2)=C1 OZLJCVCREYSDSH-WKILWMFISA-N 0.000 claims 1
- PSXGWFNAQLKJAG-HAQNSBGRSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=C)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCC=C)=C1 PSXGWFNAQLKJAG-HAQNSBGRSA-N 0.000 claims 1
- KRIQUMJZPLEHOS-QAQDUYKDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCCC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NCCC=2C=CC=CC=2)=C1 KRIQUMJZPLEHOS-QAQDUYKDSA-N 0.000 claims 1
- GAMHGYMOZVTGIY-HDJSIYSDSA-N C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NS(=O)(=O)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1NC1=NN2C=CN=C2C(NS(=O)(=O)C=2C=CC=CC=2)=C1 GAMHGYMOZVTGIY-HDJSIYSDSA-N 0.000 claims 1
- LOYSCGPAOMSQLY-SAZUREKKSA-N C1C[C@@H](N)CC[C@@H]1OC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1OC1=NN2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C1 LOYSCGPAOMSQLY-SAZUREKKSA-N 0.000 claims 1
- KKQGFRSBPBCYHJ-PUZFROQSSA-N C1C[C@@H](N)CC[C@H]1NC(C(=C1NC=2C=CC=CC=2)C=2C=CC=CC=2)=NN2C1=NC=C2 Chemical compound C1C[C@@H](N)CC[C@H]1NC(C(=C1NC=2C=CC=CC=2)C=2C=CC=CC=2)=NN2C1=NC=C2 KKQGFRSBPBCYHJ-PUZFROQSSA-N 0.000 claims 1
- AWBMLQSHYRYXRK-IZAXUBKRSA-N C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCOCC2)=C1 Chemical compound C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)C(=O)N2CCOCC2)=C1 AWBMLQSHYRYXRK-IZAXUBKRSA-N 0.000 claims 1
- FEGXYXPSNFYCNO-WOVMCDHWSA-N C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CC=C2)=C1 Chemical compound C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC(=CC=2)N2N=CC=C2)=C1 FEGXYXPSNFYCNO-WOVMCDHWSA-N 0.000 claims 1
- QITHNUYCWSICAW-OTVXOJSOSA-N C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 QITHNUYCWSICAW-OTVXOJSOSA-N 0.000 claims 1
- CQIFMGQAAVSDME-KDURUIRLSA-N C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](N)CC[C@H]1NC1=NN2C=CN=C2C(NC=2N=CC(=CC=2)C=2C=CC=CC=2)=C1 CQIFMGQAAVSDME-KDURUIRLSA-N 0.000 claims 1
- TWNMWKDKUKMFNF-KOMQPUFPSA-N C1C[C@@H](NC)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](NC)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 TWNMWKDKUKMFNF-KOMQPUFPSA-N 0.000 claims 1
- WADAIFKQPZLZDP-JCNLHEQBSA-N C1C[C@@H](NCC)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 Chemical compound C1C[C@@H](NCC)CC[C@@H]1NC1=NN2C=CN=C2C(NC=2C=CC=CC=2)=C1 WADAIFKQPZLZDP-JCNLHEQBSA-N 0.000 claims 1
- VFRFLVNATHRXHZ-SHTZXODSSA-N C=1C(N[C@@H]2CC[C@@H](N)CC2)=NN2C=CN=C2C=1N(C)C1=CC=CC=C1 Chemical compound C=1C(N[C@@H]2CC[C@@H](N)CC2)=NN2C=CN=C2C=1N(C)C1=CC=CC=C1 VFRFLVNATHRXHZ-SHTZXODSSA-N 0.000 claims 1
- JDUSRQVIGTWHDZ-YHBQERECSA-N C=1C=C(NC(=O)C=2C(N(C=3C=CC(F)=CC=3)C=CC=2)=O)C(CC)=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound C=1C=C(NC(=O)C=2C(N(C=3C=CC(F)=CC=3)C=CC=2)=O)C(CC)=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 JDUSRQVIGTWHDZ-YHBQERECSA-N 0.000 claims 1
- IFMZDRGZYWJOLA-JKIUYZKVSA-N C=1C=C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)C=CC=1C(=O)N(C)CCC1=CC=CC=N1 Chemical compound C=1C=C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)C=CC=1C(=O)N(C)CCC1=CC=CC=N1 IFMZDRGZYWJOLA-JKIUYZKVSA-N 0.000 claims 1
- ULLJEUXBGBZNIT-WKILWMFISA-N C=1C=C2NC(C)=CC2=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound C=1C=C2NC(C)=CC2=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 ULLJEUXBGBZNIT-WKILWMFISA-N 0.000 claims 1
- NTIDOVHABMQJSJ-HDJSIYSDSA-N C=1C=C2SC(C)=NC2=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound C=1C=C2SC(C)=NC2=CC=1NC(C1=NC=CN1N=1)=CC=1N[C@H]1CC[C@H](N)CC1 NTIDOVHABMQJSJ-HDJSIYSDSA-N 0.000 claims 1
- AKZJWJDJWCETKU-WGSAOQKQSA-N C=1C=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 Chemical compound C=1C=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 AKZJWJDJWCETKU-WGSAOQKQSA-N 0.000 claims 1
- OKQIMVIZRQIZOD-QAQDUYKDSA-N CC(C)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC(C)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 OKQIMVIZRQIZOD-QAQDUYKDSA-N 0.000 claims 1
- MNSXUGXCYRLMOP-WKILWMFISA-N CC(C)OC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC(C)OC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 MNSXUGXCYRLMOP-WKILWMFISA-N 0.000 claims 1
- FWEVFJZRLPAVLS-WKILWMFISA-N CC1=CC(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC(C)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 FWEVFJZRLPAVLS-WKILWMFISA-N 0.000 claims 1
- OGROFKIKOPDFFD-WKILWMFISA-N CC1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CC1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 OGROFKIKOPDFFD-WKILWMFISA-N 0.000 claims 1
- BUHZZXMHVPZDID-SHTZXODSSA-N CC1=CC(C)=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC(C)=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 BUHZZXMHVPZDID-SHTZXODSSA-N 0.000 claims 1
- BUHZZXMHVPZDID-GASCZTMLSA-N CC1=CC(C)=NC(NC=2C3=NC=CN3N=C(N[C@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC(C)=NC(NC=2C3=NC=CN3N=C(N[C@H]3CC[C@@H](N)CC3)C=2)=C1 BUHZZXMHVPZDID-GASCZTMLSA-N 0.000 claims 1
- OPJQBMTVKGKTBU-WKILWMFISA-N CC1=CC=C(C)C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC=C(C)C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 OPJQBMTVKGKTBU-WKILWMFISA-N 0.000 claims 1
- HIHCYCAYJWXOLT-HDJSIYSDSA-N CC1=CC=C(F)C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC=C(F)C(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 HIHCYCAYJWXOLT-HDJSIYSDSA-N 0.000 claims 1
- WEXAQSRMFGZJEY-SHTZXODSSA-N CC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 WEXAQSRMFGZJEY-SHTZXODSSA-N 0.000 claims 1
- JADUKQWFPFWSIJ-WKILWMFISA-N CC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1C Chemical compound CC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1C JADUKQWFPFWSIJ-WKILWMFISA-N 0.000 claims 1
- SIZSHOVMQMWOMQ-XUTJKUGGSA-N CC1=CC=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CC1=CC=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 SIZSHOVMQMWOMQ-XUTJKUGGSA-N 0.000 claims 1
- BCLSUCYWBBZQGH-WKILWMFISA-N CC1=CC=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CC1=CC=CC=C1NC1=C(C)C(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 BCLSUCYWBBZQGH-WKILWMFISA-N 0.000 claims 1
- BCLSUCYWBBZQGH-IYBDPMFKSA-N CC1=CC=CC=C1NC1=C(C)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CC1=CC=CC=C1NC1=C(C)C(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 BCLSUCYWBBZQGH-IYBDPMFKSA-N 0.000 claims 1
- UXAROFNBUIOMNS-SHTZXODSSA-N CC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 UXAROFNBUIOMNS-SHTZXODSSA-N 0.000 claims 1
- VDIAQPFLXSLDQX-HDJSIYSDSA-N CC1=CC=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CC1=CC=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 VDIAQPFLXSLDQX-HDJSIYSDSA-N 0.000 claims 1
- WTROXTYYOFDACD-WKILWMFISA-N CCC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CCC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 WTROXTYYOFDACD-WKILWMFISA-N 0.000 claims 1
- PFBBEFBXSWRIOQ-WKILWMFISA-N CCC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CCC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 PFBBEFBXSWRIOQ-WKILWMFISA-N 0.000 claims 1
- BQEOJYOGTKLFLE-SHTZXODSSA-N CCC1=CC=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CCC1=CC=NC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 BQEOJYOGTKLFLE-SHTZXODSSA-N 0.000 claims 1
- IAFVJHYMWOANDB-IYARVYRRSA-N CCN(CC)C(=O)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CCN(CC)C(=O)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 IAFVJHYMWOANDB-IYARVYRRSA-N 0.000 claims 1
- DNSPMTMZIPGNGU-JCNLHEQBSA-N CCN1N=NC(C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=N1 Chemical compound CCN1N=NC(C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=N1 DNSPMTMZIPGNGU-JCNLHEQBSA-N 0.000 claims 1
- LLKFYCDPNFVOLV-SHTZXODSSA-N CCOC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CCOC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 LLKFYCDPNFVOLV-SHTZXODSSA-N 0.000 claims 1
- VUUWCTQGQUURJP-SHTZXODSSA-N CCOC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CCOC1=CC=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 VUUWCTQGQUURJP-SHTZXODSSA-N 0.000 claims 1
- LQFFXCVPRGQCEI-SHTZXODSSA-N CN(C)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CN(C)C1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 LQFFXCVPRGQCEI-SHTZXODSSA-N 0.000 claims 1
- FDPIKTVBSOAGDX-SAABIXHNSA-N CN1C=CN=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CN1C=CN=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 FDPIKTVBSOAGDX-SAABIXHNSA-N 0.000 claims 1
- YLVUVHRTWIGXTR-JCNLHEQBSA-N CN1C=NN=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CN1C=NN=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 YLVUVHRTWIGXTR-JCNLHEQBSA-N 0.000 claims 1
- SDVICSWZZWUATH-SAABIXHNSA-N CN1N=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound CN1N=CC=C1NC(=O)C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 SDVICSWZZWUATH-SAABIXHNSA-N 0.000 claims 1
- UPESIPSZDKVMLI-HDJSIYSDSA-N COC1=CC(OC)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound COC1=CC(OC)=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 UPESIPSZDKVMLI-HDJSIYSDSA-N 0.000 claims 1
- KSQUIUIOCIKGEM-KESTWPANSA-N COC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=C1 Chemical compound COC1=CC=CC(NC(=O)C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=C1 KSQUIUIOCIKGEM-KESTWPANSA-N 0.000 claims 1
- DKGSAKUCYIJDFE-HDJSIYSDSA-N COC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound COC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 DKGSAKUCYIJDFE-HDJSIYSDSA-N 0.000 claims 1
- ZHRCNEFGIKWGDH-SHTZXODSSA-N COC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2C)=C1 Chemical compound COC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2C)=C1 ZHRCNEFGIKWGDH-SHTZXODSSA-N 0.000 claims 1
- GSQJMZCABLGAHY-HDJSIYSDSA-N CSC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound CSC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 GSQJMZCABLGAHY-HDJSIYSDSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- USHTWLJHXPYQNM-QAQDUYKDSA-N ClC1=NC=CC(N[C@@H]2CC[C@H](CC2)NC2=NN3C=CN=C3C(NC=3C=CC=CC=3)=C2)=N1 Chemical compound ClC1=NC=CC(N[C@@H]2CC[C@H](CC2)NC2=NN3C=CN=C3C(NC=3C=CC=CC=3)=C2)=N1 USHTWLJHXPYQNM-QAQDUYKDSA-N 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- WETHPAHVDNSEGZ-HDJSIYSDSA-N FC1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound FC1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 WETHPAHVDNSEGZ-HDJSIYSDSA-N 0.000 claims 1
- 241000713800 Feline immunodeficiency virus Species 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- DCDLYRUWIKFVSO-UAPYVXQJSA-N N1=C(C)C=C(C)N1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound N1=C(C)C=C(C)N1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 DCDLYRUWIKFVSO-UAPYVXQJSA-N 0.000 claims 1
- VJDLNOHUEPCCFF-HDJSIYSDSA-N N1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound N1=CC(C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 VJDLNOHUEPCCFF-HDJSIYSDSA-N 0.000 claims 1
- VJDLNOHUEPCCFF-OKILXGFUSA-N N1=CC(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound N1=CC(C)=CC=C1NC1=CC(N[C@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 VJDLNOHUEPCCFF-OKILXGFUSA-N 0.000 claims 1
- CJUABQXTORYFJG-JCNLHEQBSA-N N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(C(C)C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(C(C)C)C=1N[C@H]1CC[C@H](N)CC1 CJUABQXTORYFJG-JCNLHEQBSA-N 0.000 claims 1
- XPYOLEKDJLCFMY-KOMQPUFPSA-N N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(CC)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C(C#N)=CN=C2C(NC=2C=CC=CC=2)=C(CC)C=1N[C@H]1CC[C@H](N)CC1 XPYOLEKDJLCFMY-KOMQPUFPSA-N 0.000 claims 1
- PIMFQNOKKATHRU-HAQNSBGRSA-N N=1N2C=CN=C2C(NC(C)C)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC(C)C)=CC=1N[C@H]1CC[C@H](N)CC1 PIMFQNOKKATHRU-HAQNSBGRSA-N 0.000 claims 1
- PXPYFHZUYAWMFQ-OKILXGFUSA-N N=1N2C=CN=C2C(NC=2C(=CC=CC=2)F)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C(=CC=CC=2)F)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 PXPYFHZUYAWMFQ-OKILXGFUSA-N 0.000 claims 1
- PXPYFHZUYAWMFQ-HDJSIYSDSA-N N=1N2C=CN=C2C(NC=2C(=CC=CC=2)F)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C(=CC=CC=2)F)=C(C)C=1N[C@H]1CC[C@H](N)CC1 PXPYFHZUYAWMFQ-HDJSIYSDSA-N 0.000 claims 1
- FFUQTVMHEOZHDE-HDJSIYSDSA-N N=1N2C=CN=C2C(NC=2C=C(O)C=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=C(O)C=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 FFUQTVMHEOZHDE-HDJSIYSDSA-N 0.000 claims 1
- JYEQQYUSNBKXRA-KOMQPUFPSA-N N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C(O)=O)=C(C)C=1N[C@H]1CC[C@H](N)CC1 JYEQQYUSNBKXRA-KOMQPUFPSA-N 0.000 claims 1
- QWCSUQJRKRLRQC-AQYVVDRMSA-N N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(=CC=2)C=2C=CC=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 QWCSUQJRKRLRQC-AQYVVDRMSA-N 0.000 claims 1
- XXJDONDSTFIQFR-RVWIWJKTSA-N N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 XXJDONDSTFIQFR-RVWIWJKTSA-N 0.000 claims 1
- XXJDONDSTFIQFR-XGAFWQRZSA-N N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC(NC(=O)NC=3C=CC=CC=3)=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 XXJDONDSTFIQFR-XGAFWQRZSA-N 0.000 claims 1
- QVZLPQQDYTXASN-FZNQNYSPSA-N N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(C)C=1N[C@@H]1CC[C@H](N)CC1 QVZLPQQDYTXASN-FZNQNYSPSA-N 0.000 claims 1
- QVZLPQQDYTXASN-KOMQPUFPSA-N N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NC=2C=CC=CC=2)=C(C)C=1N[C@H]1CC[C@H](N)CC1 QVZLPQQDYTXASN-KOMQPUFPSA-N 0.000 claims 1
- YRRDINGXJANVSF-XYPYZODXSA-N N=1N2C=CN=C2C(NCC)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NCC)=CC=1N[C@H]1CC[C@H](N)CC1 YRRDINGXJANVSF-XYPYZODXSA-N 0.000 claims 1
- WBMMOWHPMPRKRG-HDJSIYSDSA-N N=1N2C=CN=C2C(NCCC(C)C)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NCCC(C)C)=CC=1N[C@H]1CC[C@H](N)CC1 WBMMOWHPMPRKRG-HDJSIYSDSA-N 0.000 claims 1
- DGTBADDJDHXMTI-HAQNSBGRSA-N N=1N2C=CN=C2C(NCCC)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NCCC)=CC=1N[C@H]1CC[C@H](N)CC1 DGTBADDJDHXMTI-HAQNSBGRSA-N 0.000 claims 1
- ABIFZPVZQNJYOU-HAQNSBGRSA-N N=1N2C=CN=C2C(NCCOC)=CC=1N[C@H]1CC[C@H](N)CC1 Chemical compound N=1N2C=CN=C2C(NCCOC)=CC=1N[C@H]1CC[C@H](N)CC1 ABIFZPVZQNJYOU-HAQNSBGRSA-N 0.000 claims 1
- HFMIBSJMBWCARP-SHTZXODSSA-N NCC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 Chemical compound NCC1=CC=CC(NC=2C3=NC=CN3N=C(N[C@@H]3CC[C@@H](N)CC3)C=2)=C1 HFMIBSJMBWCARP-SHTZXODSSA-N 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- QGQJGLQLAOMYMT-UAPYVXQJSA-N O1C(C)=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound O1C(C)=CC=C1C(C=C1)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 QGQJGLQLAOMYMT-UAPYVXQJSA-N 0.000 claims 1
- LDOOKDCZAMMTNL-HDJSIYSDSA-N OC1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 Chemical compound OC1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=CC(N[C@@H]2CC[C@@H](N)CC2)=NN2C1=NC=C2 LDOOKDCZAMMTNL-HDJSIYSDSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- TWXRAPOYZQNOJQ-SAABIXHNSA-N S1C(C)=NC(C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=C1 Chemical compound S1C(C)=NC(C=2C=CC(NC=3C4=NC=CN4N=C(N[C@@H]4CC[C@@H](N)CC4)C=3)=CC=2)=C1 TWXRAPOYZQNOJQ-SAABIXHNSA-N 0.000 claims 1
- 101100160255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YLR154C-H gene Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040550 Shigella infections Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000027950 fever generation Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- YLXWTAXPOOYRSL-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-3-carbonitrile Chemical compound C1=CC=NN2C(C#N)=CN=C21 YLXWTAXPOOYRSL-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- IMLYCDDHRGSPLB-UHFFFAOYSA-N n-(4-ethoxyphenyl)-6-(4-methyl-1,4-diazepan-1-yl)imidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CCN(C)CCC2)=NN2C1=NC=C2 IMLYCDDHRGSPLB-UHFFFAOYSA-N 0.000 claims 1
- NHTAVTVNYODDFM-UHFFFAOYSA-N n-(4-ethoxyphenyl)-6-piperazin-1-ylimidazo[1,2-b]pyridazin-8-amine Chemical compound C1=CC(OCC)=CC=C1NC1=CC(N2CCNCC2)=NN2C1=NC=C2 NHTAVTVNYODDFM-UHFFFAOYSA-N 0.000 claims 1
- ZEFXEMXDNDQMQX-UHFFFAOYSA-N n-[4-[(6-chloroimidazo[1,2-b]pyridazin-8-yl)amino]phenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NC=2C=CC(NC=3C4=NC=CN4N=C(Cl)C=3)=CC=2)=CC=C1 ZEFXEMXDNDQMQX-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000005113 shigellosis Diseases 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
Claims (19)
1. Spoj formule (I),
[image]
ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol, gdje:
E je C; F je N;
X je NR4R5;
Z je CR3;
Y je izabran između vodik, halogen, nitro, cijano, SR8, S(O)pR8, OR8, NR6R7, CO2R8, C(=O)R8, O-C(=O)R8, C(=O)NR8R9, cikloalkil, cikloalkenil, cikloalkinil, heterociklo, aril, i heteroaril, uz uvjet da ako Y je vodik tada R4 je fenil supstituiran karboksamido skupinom;
R1 i R2 su nezavisno izabrani između (i) vodik, alkil, halogen, nitro, cijano, SR10, OR10, NR10R11, NR10C(=O)R11, CO2R10, C(=O)R10, -O-C(=O)R10, C(=O)NR10R11;
R3 je izabran između vodik, halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil alkinil, supstituirani alkinil, nitro, cijano, SR13, OR13, NR13R14, NR13C(=O)R14, CO2R13, C(=O)R13, -O-C(=O)R13, -C(=O)NR13R14, cikloalkil, heterociklo, aril, i heteroaril;
R4, R5, R6, i R7 su nezavisno izabrani između vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, OR15, SR15, C(=O)R15, CO2R15, C(=O)NR15R16, C(W)OR16, S(O)pR17, SO2NR15R16, cikloalkil, heterociklo, aril, i heteroaril; ili (ii) R4 je uzet zajedno s R5 i atomom dušika za koji su oba spojeni i/ili R6 je uzet zajedno s R7 i atomom dušika za koji su oba spojeni da formiraju heteroaril ili heterocikl;
R8, R9, R10, R11, R13, R14, R15, i R16 pri svakom pojavljivanju su nezavisno izabrani između (i) vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil, aril, heteroaril, i heterociklo; ili (ii) zajedno s atomom dušika za koji su spojeni, R8 je uzet zajedno s R9, i/ili R10 je uzet zajedno s R11, i/ili R13 je uzet zajedno s R14, i/ili R15 je uzet zajedno s R16 da formiraju heteroaril ili heterocikl;
R17 je izabran između alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil, aril, heteroaril, i heterociklo;
W pri svakom pojavljivanju je O, S, N, CN, ili NH; i
p je 1 ili 2,
uz sljedeće uvjete:
(1) ako X je NH(Me), N(Me)2, NH(nesupstituirani fenil), ili NHNH2, tada Y je nešto osim vodika ili halogena; i
(2) sljedeći spojevi su isključeni:
[image]
2. Spoj prema zahtjevu 1 s formulom (Ia)
[image]
ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 2, ili ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje:
R4 je -AM;
R5 je vodik ili C1-4alkil;
ili R4 i R5 zajedno s atomom dušika za koji su spojeni formiraju 5-, 6- ili 7-eročlani monociklički heteroarilni ili heterociklički prsten, ili 7- do 11-eročlani biciklički heteroarilni ili heterociklički prsten, svaki prsten je po izboru supstituiran jednom do tri skupine, T1, T2; i/ili T3;
A je veza, C1-3alkilen, C2-4alkenilen, C2-4alkinilen, -C(O)-, ili -SO2-;
M je (i) vodik, alkil, alkoksi, ili alkenil; ili (ii) cikloalkil, heterociklo, aril, ili heteroaril, svaka skupina je po izboru supstituirana jednom do tri skupine, T1, T2, i/ili T3;
T1, T2, i T3 su nezavisno izabrani između (i) halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, nitro, cijano, SO3H SR19, S(O)pR21, S(O)pNR19R20, NR19S(O)pR21, OR19, NR19R20, NR19C(=O)20, NR19C(=O)NR19R20, CO2R19, C(=O)R19, -O-C(=O)R19, -C(=O)NR19R20, cikloalkil, heterociklo, aril, i heteroaril, gdje p je jedan ili 2; i/ili (ii) dvije skupine, T1 i T2, smještene na susjednim atomima u prstenu su uzete zajedno s atomima prstena za koje su spojene da formiraju fuzionirani cikloalkil, aril, heteroaril, ili heterociklo;
R19, R20, i R21 pri svakom pojavljivanju, izabiru se nezavisno između (i) vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, cikloalkil, aril, heteroaril, i heterociklo; ili (ii) R19 i R20 zajedno s atomom dušika za koji su oba spojeni formiraju heteroaril ili heterociklo; i
R21 pri svakom pojavljivanju, je izabran između alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil, aril, heteroaril, i heterociklo.
4. Spoj prema zahtjevu 2, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje:
Y je vodik, halogen, OR8, ili NR6R7;
R6 je izabran između vodik ili C1-4alkil po izboru supstituiranih jednom ili tri skupine izabrane između halogen, C1-4alkil, nitro, cijano, amino, C1-4alkoksi, i OH;
R7 i R8 su nezavisno izabrani između alkil, cikloalkil, heterociklo, aril, i heteroaril, svaka skupina je po izboru supstituirana jednom ili tri skupine, T4, T5, i/ili T6;
ili R6 i R7 zajedno s atomom dušika za koji su spojeni formiraju heteroarilni ili heterociklički prsten, svaki prsten je po izboru supstituiran jednom do tri skupine, T4, T5, i/ili T6;
T4, T5 i T6 su nezavisno izabrani između (i) halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, nitro, cijano, SR19, OR19, NR19R20, NR19C(=O)R20, CO2R19, C(=O)R19, -O-C(=O)R19, -C(=O)NR19R20, cikloalkil, heterociklo, aril, i heteroaril; i/ili (ii) dvije skupine, T4 i T5, supstituirane na susjednim atomima prstena su uzete zajedno s atomima prstena za koje su spojene da formiraju fuzionirani cikloalkil, heterociklo, aril, ili heteroaril; i R19 i R20, pri svakom pojavljivanju izabiru se nezavisno između (i) vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, cikloalkil, aril, heteroaril, i heterociklo; ili
(ii) R19 s R20 zajedno s atomom dušika za koji su oba spojeni, kombiniraju se da formiraju heteroaril ili heterocikl.
5. Spoj formule (Ia) :
[image]
ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol, gdje:
X je NR4R5;
Y je vodik, halogen, OR8, ili NR6R7;
R1 i R2 su nezavisno izabrani između (i) vodik, alkil, halogen, nitro, cijano, SR10, OR10, NR10R11, NR10C(=O)R11, CO2R10, C(=O)R10, -O-C(=O)R10, C(=O)NR10R11;
R3 je izabran između vodik, halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, nitro, cijano, SR13, OR13, NR13R14, NR13C(=O)R14, CO2R13, C(=O)R13, -O-C(=O)R13, -C(=O)NR13R14, cikloalkil, heterociklo, aril, i heteroaril;
R4 je -AM;
R5 je vodik ili C1-4alkil;
ili R4 i R5 zajedno s atomom dušika za koji su spojeni formiraju 5-, 6- ili 7-eročlani monociklički heteroarilni ili heterociklički prsten, ili 7- do 11-eročlani biciklički heteroarilni ili heterociklički prsten, svaki prsten je po izboru supstituiran jednom do tri skupine, T1, T2; i/ili T3;
A je veza, C1-3alkilen, C2-4alkenilen, C2-4alkinilen, -C(O)-, ili -SO2-; M je (i) vodik, NR15R16, alkil, alkoksi, ili alkenil; ili (ii) cikloalkil, heterociklo, aril, ili heteroaril, svaki prsten je po izboru supstituiran jednom do tri skupine, T1, T2, i/ili T3;
R6 je izabran između vodik ili C1-4alkil po izboru supstituiranih jednom ili tri skupine izabrane između halogen, C1-4alkil, nitro, cijano, amino, C1-4alkoksi, i OH;
R7 je izabran između alkil, cikloalkil, heterociklo, aril, i heteroaril, svaka skupina je po izboru supstituirana jednom ili tri skupine, T4, T5, i/ili T6;
ili R6 i R7 zajedno s atomom dušika za koji su spojeni formiraju heteroarilni ili heterociklički prsten, svaki prsten je po izboru supstituiran jednom do tri skupine, T4, T5, i/ili T6;
R8 je izabran između alkil, cikloalkil, heterociklo, aril, i heteroaril, svaka skupina je po izboru supstituirana jednom ili tri skupine, T4, T5, i/ili T6;
R10, R11, R13, i R14 pri svakom pojavljivanju su nezavisno izabrani između (i) vodik, C1-4alkil, i supstituirani C1-4alkil; ili (ii) R10 i R11 zajedno s atomom dušika za koji su oba spojeni, i/ili R13 i R14 zajedno s atomom dušika za koji su oba spojeni se kombiniraju da formiraju po izboru supstituirani 5-, 6-, ili 7-eročlani heteroaril ili heterociklo;
R15 i R16 su nezavisno izabrani između (i) vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil, aril, heteroaril, i heterociklo; ili (ii) zajedno s atomom dušika za koji su spojeni R15 je uzet zajedno s R16 da formiraju heteroaril ili heterocikl;
T1, T2, i T3 su nezavisno izabrani između (i) halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, nitro, cijano, SO3H SR19, S(O)pR21, S(O)pNR19R20, NR19S(O)pR21 , OR19, NR19R20, NR19C(=O)20, NR19C(=O)NR19R20, CO2R19, C(=O)R19, -O-C(=O)R19, -C(=O)NR19R20, cikloalkil, heterociklo, aril, i heteroaril, gdje p je jedan ili 2; i/ili (ii) dvije skupine, T1 i T2, smještene na susjednim atomima u prstenu su uzete zajedno s atomima prstena za koje su spojene da formiraju fuzionirani cikloalkil, aril, heteroaril, ili heterociklo;
T4, T5 i T6 su nezavisno izabrani između (i) halogen, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, nitro, cijano, SR19, OR19, NR19R20, NR19C(=O)R20, CO2R19, C(=O)R19, -O-C(=O)R19, -C(=O)NR19R20, cikloalkil, heterociklo, aril, i heteroaril; i/ili (ii) dvije skupine, T4 i T5, supstituirane na susjednim atomima prstena su uzete zajedno s atomima prstena za koje su spojene da formiraju fuzionirani cikloalkil, heterociklo, aril, ili heteroaril; i
R19 i R20 pri svakom pojavljivanju izabiru se nezavisno između (i) vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, cikloalkil, aril, heteroaril, i heterociklo; ili (ii) R19 i R20 zajedno s atomom dušika za koji su oba spojeni formiraju heteroarilni ili heterociklički prsten; i
R21 pri svakom pojavljivanju, je izabran između alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil, aril, heteroaril, i heterociklo;
uz sljedeće uvjete:
(1) ako X je NH(Me), N(Me)2, NH(nesupstituirani fenil), ili NHNH2, tada Y je nešto osim vodika ili halogena; i
(2) sljedeći spojevi su isključeni:
[image]
6. Spoj prema zahtjevu 5, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje:
R4 je -AM;
A je veza, -C(O)-, ili -S(O)2-, ili C1-3alkilen;
M je (i) vodik, -NH(aril), C1-6alkil, C2-4alkenil, ili -OC1-4alkil ili (ii) C3-6cikloalkil, fenil, fluorenil, 1-naftil, ili 2-naftil, svaka skupina je po izboru supstituirana jednom do tri skupine, T1, T2, i/ili T3; ili (iii) 5-, 6- ili 7-eročlani monocikl ili 7- do 11-eročlani biciklički heteroarilni ili heterociklički prsten, svaki prsten je po izboru supstituiran jednom do tri skupine, T1, T2, i/ili T3; i
T1, T2, i T3 su nezavisno izabrani između (i) C1-4alkil, supstituirani C1-4alkil, C1-4alkiloksi, supstituirani C1-4alkiloksi, C1-4alkiltio, fenoksi, -NR19R20, halogen, hidroksi, cijano, SO3H, COOH, -C(O)(R19), C(O)NR19R20, NR19C(O)R20, S(O)2R21, S(O)2NR19R20 i NR19(C(O)NR19R20; i/ili (ii) fenil, ciklopropil, cikloheksil, tetrazolil, imidazolil, pirazolil, triazolil, tiazolil, furil, i morfolinilod kojih je svaka skupina po izboru supstituirana kako valencija dopušta s jednom do tri skupine, R22, R23 i/ili R24; i/ili (iii) dvije skupine, T1 i T2, supstituirane na susjednim atomima prstena su uzete zajedno s atomima prstena za koje su spojene da formiraju fuzionirani pet- do sedmeročlani cikloalkil, fuzionirani fenil ili fuzionirani 5- ili 6-eročlani heterocikl ili heteroaril od kojih je svaka skupina po izboru supstituirana kako valencija dopušta s jednom do tri skupine, R22, R23 i/ili R24; i
R19 i R20 pri svakom pojavljivanju izabiru se nezavisno između (i) vodik, -(CH2)vOH, i C1-4alkil; ili (ii) -(CH2)vcikloheksil, -(CH2)vfenil, -(CH2)vmorfolinil, - (CH2)vpiridil, -(CH2)vpirazolil, -(CH2)vciklopropil, -(CH2)vpirolidinil, - (CH2)vpiperidinil, -(CH2)vfuril, -(CH2)vimidazolil, -(CH2)vpirimidinil, - (CH2)vpiperazinil, i -(CH2)vpiradizinil od kojih je svaka skupina po izboru supstituirana kako valencija dopušta s jednom do tri skupine, R22, R23 i/ili R24; ili R19 i R20 su uzeti zajedno s atomom dušika za koji su oba spojeni da formiraju pirolinidil, morfolinil, piperidinil, piradazinil, ili piperazinil od kojih je svaka skupina po izboru supstituirana kako valencija dopušta s jednom do tri skupine, R22, R23 i/ili R24;
R21 pri svakom pojavljivanju je izabran između (i) -(CH2)vOH, i C1-4alkil; ili (ii) - (CH2)vcikloheksil, -(CH2)vfenil, -(CH2)vmorfolinil, -(CH2)vpiridil, - (CH2)vpirazolil, -(CH2)vciklopropil, -(CH2)vpirolidinil, -(CH2)vpiperidinil, - (CH2)vfuril, -(CH2)vimidazolil, -(CH2)vpirimidinil, -(CH2)vpiperazinil, i - (CH2)vpiradizinil od kojih je svaka skupina po izboru supstituirana kako valencija dopušta s jednom do tri skupine, R22, R23 i/ili R24; R22, R23, i R24 pri svakom pojavljivanju, izabiru se nezavisno između (C1-4)alkil, (C2-4)alkenil, halogen, hidroksi, cijano, nitro, CF3, =O, O(C1-4alkil), OCF3, C(=O)H, C(=O)(C1-4alkil), CO2H, CO2(C1-4alkil), NHCO2(C1-4alkil), -S(C1-4alkil), -NH2, NH(C1-4alkil), N(C1-4alkil)2, N(C1-4alkil)3+, SO2(C1-4alkil), C(=O)(C1-4alkilen)NH2, C(=O)(C1-4alkilen)NH(alkil), C(=O)(C1-4alkilen)N(C1-4alkil)2, i po izboru supstituirani fenil; i v je 0, 1, 2, ili 3.
7. Spoj prema zahtjevu 6, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol, gdje NR4R5 je izabran između sljedećeg:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
8. Spoj prema zahtjevu 5, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje:
Y je NR6R7;
R6 je izabran između vodik ili C1-4alkil;
R7 je izabran između C1-4alkil, ciklopentil, cikloheksil, biciklo[2.2.2]oktil, pirolidinil, i piperidinil, svaka skupina je po izboru supstituirana jednom ili tri skupine, T4, T5, i/ili T6;
ili R6 i R7 zajedno s atomom dušika za koji su spojeni formiraju piperazinil, piperidinil, pirolidinil, ili diazepanil, svaka skupina je po izboru supstituirana jednom ili tri skupine, T4, T5, i/ili T6; i
T4, T5, i T6 su nezavisno izabrani između (i) C1-4alkil, OH, NH2, NH(C1-4alkil), furil, i N(C1-4alkil)2, i NH(pirimidinil) gdje je pirimidinil supstituiran halogenom; ili (ii) C1-4alkil supstituiran cikloheksilom ili OH, gdje je cikloheksil supstituiran s NH2.
9. Spoj prema zahtjevu 8, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje NR6R7 je izabran između sljedećeg: NH-(CH2)2-NH2, NH-(CH2)4-NH2,
[image]
10. Spoj prema zahtjevu 8, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje NR6R7 je izabran između:
[image]
[image]
i
[image]
11. Spoj prema zahtjevu 5, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol gdje R5 je vodik i R4 je izabran između fenil, piridil, pirimidinil, cikloheksil, i piperidinil prstena, svaki prsten je po izboru supstituiran jednom do dvije skupine, T1, i/ili T2.
12. Spoj prema zahtjevu 1 ili 5, ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol, gdje:
R1 i R2 su nezavisno izabrani između vodik, halogen, OR10, cijano, C1-4alkil, CO2R10, i C(O)NR10R11;
R3 je izabran između (i) vodik, halogen, nitro, cijano, OR10, NR10R11, CO2R10, i C(=O)R10, (ii) C1-4alkil, supstituirani C1-4alkil, cikloalkil, aril, i heteroaril; i
R10 i R11 su nezavisno izabrani između (i) vodik, C1-4alkil, i supstituirani C1-4alkil; ili (ii) R10 i R11 zajedno s atomom dušika za koji su oba spojeni kombiniraju se da formiraju po izboru supstituirani 5-, 6-, ili 7-eročlani heteroaril ili heterociklo.
13. Spoj prema zahtjevu 1 ili 5 gdje spoj ima formulu (Ia),
[image]
ili njegov enantiomer, diastereomer, ili farmaceutski prihvatljiva sol.
14. Spoj izabran između sljedećih:
(i)
N6-(trans-4-aminocikloheksil)-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin,
N6-(2-aminoetil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(4-aminobutil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
7-klor-N-(4-(etiloksi)fenil)-6-(1-piperazinil)imidazo[1,2-b]piridazin-8-amin;
N6-(trans-4-aminocikloheksil)-N8-(4-(metiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(metiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,4-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(feniloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(butiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-4-bifenililimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,4-bis(metiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-((fenilmetil)oksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(propiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-piridin-3-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-metil-1H-indol-5-il)imidazo[1,2-b]piridazin-6,8-diamin;;
N6-(trans-4-aminocikloheksil)-N8-metil-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-[2-(metiloksi)fenillimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,3-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,4-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,5-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,5-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-[3-(dimetilamino)fenil] imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-metil-1,3-benzotiazol-6-il)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-metil-1,3-benzotiazol-5-il)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-ciklopropilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-cikloheksilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(cikloheksilmetil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(1-metiletil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(fenilmetil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-[(2-klorfenil)metil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-((4-klorfenil)metil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-((4-(metiloksi)fenil)metil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-etilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-(metiloksi)etil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-(4-(metiloksi)fenil)etil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-2-propen-1-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-metilbutil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-propilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(ciklopropilmetil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-((3-klorfenil)metil)imidazo[1,2-b]piridazin-6,8-diamin;
6-(3-amino-1-piperidinil)-N-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-8-amin
N6-(3-aminopropil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,6-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(4-((4-aminocikloheksil)metil)cikloheksil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
2-(1-(8-((4-(etiloksi)fenil)amino)imidazo[1,2-b]piridazin-6-il)-4-piperidinil)etanol;
N6-(trans-4-aminocikloheksil)-N8-1H-indol-5-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
6-(3-amino-1-pirolidinil)-N-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-8-amin
N6-(trans-4-aminocikloheksil)-N8-(2-feniletil)imidazo[1,2-b]piridazin-6,8-diamin;
N-(4-(etiloksi)fenil)-6-(1-piperazinil)imidazo[1,2-b]piridazin-8-amin
N6-(2-(dimetilamino)etil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N8-(4-(etiloksi)fenil)-N6-(2-furanilmetil)imidazo[1,2-b]piridazin-6,8-diamin;
N-(4-(etiloksi)fenil)-6-(4-metil-1,4-diazepan-1-il)imidazo[1,2-b]piridazin-8-amin ;
2-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenol ;
N6-(trans-4-aminocikloheksil)-N8-(3-((fenilmetil)oksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenol ;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenol ;
N6-(trans-4-aminocikloheksil)imidazo[1,2-b]piridazin-6,8-diamin;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzonitril ;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzonitril ;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzojeva kiselina;
N6-(trans-4-aminocikloheksil)-N8-1H-pirazol-3-ilimidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzojeva kiselina ;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,Ndimetilbenzensulfonamid;
N6-(trans-4-aminocikloheksil)-N8-(4-(1H-tetrazol-5-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin; ;
N6-(trans-4-(etilamino)cikloheksil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-(metilamino)cikloheksil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-(feniloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4’-klor-4-bifenilil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2’-metil-4-bifenilil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3’-klor-4-bifenilil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(fenilmetil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(4-morfolinil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3’-klor-3-bifenilil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1-metiletil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-butilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(5,6,7,8-tetrahidro-1-naftalenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-1-naftalenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(fenilmetil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-propilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4’-metil-4-bifenilil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(1-metiletil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-((1-metiletil)oksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,5-bis(metiloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
trans-N-(8-(6-metil-3,4-dihidro-1(2H)-kinolinil)imidazo[1,2-b]piridazin-6-il)-1,4-cikloheksandiamin;
N6-(trans-4-aminocikloheksil)-N8-2-naftalenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(metilsulfanil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-etilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-etilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(metilsulfanil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-9H-fluoren-2-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-etilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-cikloheksilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1,1-dimetiletil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(feniloksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-3-bifenililimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-((1-metiletil)oksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-klorfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-klorfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-klorfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-klor-1-naftalenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-3-kinolinilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,5-diklorfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(trifluorometil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-klor-2-fluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-fluoro-5-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-klor-3-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(5-fenil-2-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-fluoro-4-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-metil-4-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-fluoro-3-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-fluoro-4-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-((trifluorometil)oksi)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-metil-3-(trifluorometil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-etil-2-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1H-1,2,4-triazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1H-pirol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(4,5-diklor-1H-imidazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1H-pirazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(3,5-dimetil-1H-pirazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(4-metil-4H-1,2,4-triazol-3-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1H-imidazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1-metil-1H-imidazol-2-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(2-metil-1,3-tiazol-4-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(5-metil-2-furanil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(2-etil-2H-tetrazol-5-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-3-hidroksi-N,N-dimetilbenzensulfonamid ;
N6-(trans-4-aminocikloheksil)-N8-(2,3-dihidro-1H-inden-5-il)imidazo[1,2-b]piridazin-6,8-diamin;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,Ndimetilbenzensulfonamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,N-dimetilbenzamid ;
N6-(trans-4-((2-klor-4-pirimidinil)amino)cikloheksil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(3-aminociklopentil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-(4-morfolinilsulfonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,N-dietilbenzamid
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-metil-N-fenilbenzensulfonamid
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-2-hidroksi-N,N-dimetilbenzensulfonamid
N6-(4-aminobiciklo[2.2.2]oct-1-il)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenil)metansulfonamid;
N6-(trans-4-aminocikloheksil)-N8-(4-(3-(dimetilamino)-1-pirolidinil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1-pirolidinilsulfonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzensulfonska kiselina;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,N-dietilbenzensulfonamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-propilbenzensulfonamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-etilbenzensulfonamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-metilbenzensulfonamid;
N6-(trans-4-aminocikloheksil)-N8-(4-aminofenil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzensulfonamid ;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzensulfonamid ;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzamid ;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)benzamid ;
N6-(trans-4-aminocikloheksil)-N8-(4-(aminometil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
6-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-1,2-dihidro-3H-indazol-3-on ;
N6-(trans-4-aminocikloheksil)-N8-(3-(aminometil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,6-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-klor-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(3-aminopropil)-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-fluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,6-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,4-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-fluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-fluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,4-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,5-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2,3-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,5-difluorofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3-jodofenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-[4-(trifluorometil)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-piridin-2-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-metilpiridin-2-il)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(5-metilpiridin-2-il)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4,6-dimetilpiridin-2-il)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-pirimidin-2-ilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-[4-(etiloksi)fenil]-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-etil-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-metil-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(3,4-dimetilfenil)-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-metil-N8-(4-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-metil-N8-[3-(metiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-bifenil-4-il-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-metil-N8-[4-(propiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)benzojeva kiselina;
4-((6-((4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)-N,N-dimetilbenzensulfonamid;
N-(4-((6-((trans-4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)fenil)-N-metilacetamid;
N6-(trans-4-aminocikloheksil)-7-etil-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-klor-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
N8-[4-(etiloksi)fenil]-N6-piperidin-3-ilimidazo[1,2-b]piridazin-6,8-diamin;
N8-[4-(etiloksi)fenil]-N6-pirolidin-3-ilimidazo[1,2-b]piridazin-6,8-diamin;
N8-[4-(etiloksi)fenil]-N6-piperidin-4-ilimidazo[1,2-b]piridazin-6,8-diamin;
6-(3-amino-1-piperidinil)-N-(4-(etiloksi)fenil)imidazo[1,2-b]piridazin-8-amin;
N8-(4-(etiloksi)fenil)-7-metil-N6-3-piperidinilimidazo[1,2-b]piridazin-6,8-diamin;
N8-fenil-N6-3-piperidinilimidazo[1,2-b]piridazin-6,8-diamin;
6-[(3S)-3-aminopirolidin-1-il]-N-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-8-amin;
N6-(cis-4-aminocikloheksil)-N8-[4-(etiloksi)fenil]-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(5-metil-2-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-7-metil-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(4-(etiloksi)fenil)imidazo[1,2-b] piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(3,4-dimetilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(5-fenil-2-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((cis-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,N-dimetilbenzensulfonamid;
N6-(cis-4-aminocikloheksil)-N8-(4-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(4,6-dimetil-2-piridinil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(4-(1H-pirazol-1-il)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(4-(4-morfolinilkarbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-7-metil-N8-(2-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(2-fluorofenil)-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-7-metil-N8-(2-metilfenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(2-fluorofenil)-7-metilimidazo[1,2-b]piridazin-6,8-diamin;
N-(6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)benzamid;
1-(6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)-3-fenilurea;
N,N’-bis(4-trans-aminocikloheksil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-etiloksifenil)-7-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(fenil)-7-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(fenil)-7-fenilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(cis-4-aminocikloheksil)-N8-(4-etoksifenil)-7-fenilimidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(2-(4-piridinil)etil)benzamid
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(2-furanilmetil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(1H-imidazol-4-ilmetil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(3-piridinilmetil)benzamid;
N6-(trans-4-aminocikloheksil)-N8-(4-((4-fenil-1-piperidinil)karbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1-pirolidinilkarbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(1-piperidinilkarbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(fenilmetil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(3-(metiloksi)fenil)benzamid;
N6-(trans-4-aminocikloheksil)-N8-(4-((3-fenil-1- pirolidinil)karbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
3-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-fenilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(2-hidroksietil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(3-(2-okso-1-pirolidinil)propil)benzamid;
N6-(trans-4-aminocikloheksil)-N8-(4-(4-morfolinilkarbonil)fenil)imidazo[1,2-b]piridazin-6,8-diamin;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-metil-N-(2-(2-piridinil)etil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N,N-dietilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-ciklopropilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(cikloheksilmetil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-3-piridinilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(1-metil-1H-pirazol-5-il)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(1-(4-fluorofenil)-2-okso-1,2-dihidro-3-piridinil)benzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-fenilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-cikloheksilbenzamid;
4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-N-(4-piridinilmetil)benzamid;
1-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenil)-3-fenilurea;
1-(4-((6-((cis-4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)fenil)-3-fenilurea;
1-(4-((6-((trans-4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)fenil)-3-fenilurea;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenil)-1-(4-fluorofenil)-2-okso-1,2-dihidro-3-piridinkarboksamid;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-fenil)-1-(4-fluorofenil)-2-okso-1,2-dihidro-3-piridinkarboksamid;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)-2-etilfenil)-1-(4-fluorofenil)-2-okso-1,2-dihidro-3-piridinkarboksamid;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenil)benzamid;
N-(4-((6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)amino)fenil)acetamid;
3-((6-((trans-4-aminocikloheksil)amino)-7-metilimidazo[1,2-b]piridazin-8-il)amino)fenol;
N-(4-((6-klorimidazo[1,2-b]piridazin-8-il)amino)fenil)-1-(4-fluorofenil)-2-okso-1,2-dihidro-3-piridinkarboksamid;
1-(4-fluorofenil)-N-(4-(imidazo[1,2-b]piridazin-8-ilamino)fenil)-2-okso-3-piperidinkarboksamid;
1-(4-fluorofenil)-N-(4-(imidazo[1,2-b]piridazin-8-ilamino)fenil)-2-okso-1,2-dihidro-3-piridinkarboksamid;
6-((trans-4-aminocikloheksil)amino)-8-((4-(etiloksi)fenil)amino)imidazo[1,2-b]piridazin-3-karbonitril;
6-((trans-4-aminocikloheksil)amino)-8-(fenilamino)imidazo[1,2-b]piridazin-3 - karbonitril ;
6-((4-trans-aminocikloheksil)amino)-7-metil-8-(fenilamino)imidazo[1,2-b]piridazin-3-karbonitril;
6-((trans)-4-aminocikloheksilamino)-7-etil-8-(fenilamino)imidazo[ 1,2-b]piridazin-3-karbonitril;
6-((trans-4-aminocikloheksil)amino)-8-anilino-7-izopropilimidazo[1,2-b]piridazin-3-karbonitril ;
N6-(trans-4-aminocikloheksil)-N8-(4-(etiloksi)fenil)-3-fluoroimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(etiloksi)fenil)-3-metilimidazo[1,2-b]piridazin-6,8-diamin;
N6-(trans-4-aminocikloheksil)-N8-(4-(etiloksi)fenil)-2,3-dimetilimidazo[1,2-b]piridazin-6,8-diamin;
N-(6-((trans-4-aminocikloheksil)amino)imidazo[1,2-b]piridazin-8-il)benzensulfonamid;
6-((trans-4-aminocikloheksil)oksi)-8-anilinoimidazo[1,2-b]piridazin-3-karbonitril;
6-((trans-4-aminocikloheksil)amino)-8-anilinoimidazo[1,2-b]piridazin-3-karboksamid ;
N6-(trans-4-aminocikloheksil)-7-etil-N8-fenilimidazo[1,2-b]piridazin-6,8-diamin; i
N6-(trans-4-aminocikloheksil)-7-etil-N8-[4-(etiloksi)fenil]imidazo[1,2-b]piridazin-6,8-diamin;
ii) ili enantiomer, diastereomer, ili farmaceutski prihvatljiva sol od (i).
15. Farmaceutska smjesa koja sadrži jedan ili više spojeva prema zahtjevu 1 ili 14 i farmaceutski prihvatljiv nosač ili punilo.
16. Spoj prema zahtjevu 1 ili 14 za uporabu u liječenju, kod sisavca, pankreatitisa (akutnog ili kroničnog), astme, alergija, respiratornog stres sindroma kod odraslih, kronične opstruktivne plućne bolesti, glomerulonefritisa, reumatoidnog artritisa, sistemskog lupusa eritematosis, skleroderme, kroničnog tiroiditisa, Graveove bolesti, autoimunog gastritisa, dijabetesa, autoimune hemolitičke anemije, autoimune neutropenije, trombocitopenije, atopijskog dermatitisa, kroničnog aktivnog hepatitisa, miastenije gravis, multiple skleroze, upalne bolesti crijeva, ulceroznog kolitisa, Crohnove bolesti, psorijaze, bolesti transplantant protiv domaćina, upalne reakcije inducirane endotoksinom, tuberkuloze, ateroskleroze, degeneracije mišića, kaheksije, psorijatičnog artritisa, Reiterovog sindroma, gihta, traumatskog artritisa, rubella artritisa, akutnog sinovitisa, bolesti β-stanica gušterače; bolesti karakterizirane masivnom infiltracijom neutrofila, reumatoidnog spondilitisa, giht artritisa i drugih artritičnih stanja, cerebralne malarije, kronične pulmonarne inflamatorne bolesti, silikoze, plućne sarkoidoze, bolesti resorpcije kosti, odbijanja alografta, vrućice i mijalgija infekcije, kaheksije sekundarne infekciji, nastanka meloida, nastanka ožiljnog tkiva, ulceroznog kolitisa, pireze, gripe, osteoporoze, osteoartritisa, akutne mijelogenične leukemije, kronične mijelogenične leukemije, metastatskog melanoma, Kaposijevog sarkoma, multiplog mijeloma, sepse, septičnog šoka, i Shigeloze; Alzheimerove bolesti, Parkinsonove bolesti, cerebralnih ishemija ili neurodegenerativnih bolesti uzrokovanih traumatskom ozljedom; angiogeničnih poremećaja uključujući solidne tumore, okularne neovaskulizacije, i infantilnih hemangioma; infekcije akutnog hepatitisa (uključujući hepatitis A, hepatitis B i hepatitis C), HIV infekcije i CMV retinitisa, AIDS, ARC ili malignosti, i herpesa; moždanog udara, ishemije miokarda, ishemije kod moždanog udara i srčanih udara, hipozije organa, vaskularne hiperplazije, reperfuzijske ozljede srca i bubrega, tromboze, hipertrofije srca, agregacije trombocita izazvane trombinom, endotoksemije i/ili sindroma toskičnog šoka, stanja povezanih sa prostaglandin endoperoksidazom sintazom-2, edema, analgezije, neuromuskularne boli, glavobolje, boli uzrokovane rakom, bol zuba, artritična bol, konjskog zaraznog virusa anemije, mačjeg virusa imunodeficijencije, goveđeg virusa imunodeficijencije, psećeg virusa imunodeficijencije, i pemphigus vulgaris.
17. Spoj za uporabu u liječenju prema zahtjevu 16 gdje se stanje izabire između Crohnove bolesti i ulceroznog kolitisa, odbijanja alografta, reumatoidnog artritisa, psorijaze, ankilozantnog spondilitisa, psorijatičnog artritisa, i pemphigus vulgaris.
18. Spoj za uporabu u liječenju prema zahtjevu 16 gdje se stanje izabire između ishemijske reperfuzijske ozljede, uključujući cerebralnu ishemijsku reperfuzijsku ozljedu nastalu zbog moždanog udara te ishemijsku reperfuzijsku ozljedu srca nastalu zbog infarkta miokarda.
19. Spoj za uporabu u liječenju prema zahtjevu 16 gdje je stanje multipli mijelom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71951905P | 2005-09-22 | 2005-09-22 | |
US11/524,996 US20070078136A1 (en) | 2005-09-22 | 2006-09-21 | Fused heterocyclic compounds useful as kinase modulators |
PCT/US2006/037056 WO2007038314A2 (en) | 2005-09-22 | 2006-09-22 | Fused heterocyclic compounds useful as kinase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130155T1 true HRP20130155T1 (hr) | 2013-03-31 |
Family
ID=37716206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130155TT HRP20130155T1 (hr) | 2005-09-22 | 2013-02-25 | Fuzionirani heterocikliäśki spojevi korisni kao modulatori kinaze |
Country Status (24)
Country | Link |
---|---|
US (1) | US20070078136A1 (hr) |
EP (1) | EP1928879B1 (hr) |
JP (1) | JP5241498B2 (hr) |
KR (2) | KR101399766B1 (hr) |
AR (1) | AR055177A1 (hr) |
AU (1) | AU2006295439B2 (hr) |
BR (1) | BRPI0616393B8 (hr) |
CA (1) | CA2623369C (hr) |
CY (1) | CY1114001T1 (hr) |
DK (1) | DK1928879T3 (hr) |
EA (1) | EA017632B1 (hr) |
ES (1) | ES2402664T3 (hr) |
GE (1) | GEP20104943B (hr) |
HR (1) | HRP20130155T1 (hr) |
IL (1) | IL190280A (hr) |
NO (1) | NO20081231L (hr) |
NZ (1) | NZ566663A (hr) |
PE (1) | PE20070520A1 (hr) |
PH (1) | PH12013501329A1 (hr) |
PL (1) | PL1928879T3 (hr) |
PT (1) | PT1928879E (hr) |
SI (1) | SI1928879T1 (hr) |
TW (2) | TWI478925B (hr) |
WO (1) | WO2007038314A2 (hr) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007002261A1 (es) | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
EP2125819B1 (en) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
US8143253B2 (en) * | 2007-07-26 | 2012-03-27 | Novartis Ag | Organic compounds |
WO2009067621A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
KR20100090289A (ko) * | 2007-11-21 | 2010-08-13 | 디코드 제네틱스 이에이치에프 | 염증, 심혈관 및 중추신경계 질환의 치료를 위한 치환된 벤조아졸 pde4 억제제 |
KR101608096B1 (ko) * | 2008-01-23 | 2016-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | 4-피리디논 화합물 및 암을 위한 그의 용도 |
JP5394404B2 (ja) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
KR20100128305A (ko) | 2008-02-28 | 2010-12-07 | 노파르티스 아게 | C-met 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-b]피리다진 유도체 |
MX2010010151A (es) * | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
HUE034716T2 (hu) * | 2008-05-21 | 2018-02-28 | Incyte Holdings Corp | 2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására |
CN102164604A (zh) | 2008-07-24 | 2011-08-24 | 百时美施贵宝公司 | 用作激酶调节剂的稠合杂环化合物 |
UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
WO2010027114A1 (en) * | 2008-09-05 | 2010-03-11 | Choongwae Pharma Corporation | Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
KR101634833B1 (ko) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
WO2010068810A2 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
PA8854101A1 (es) * | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
EP2391602B1 (en) | 2008-12-19 | 2013-12-04 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
EA019685B1 (ru) * | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы |
TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
JP5559309B2 (ja) | 2009-05-07 | 2014-07-23 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体 |
EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
KR20120050450A (ko) | 2009-07-15 | 2012-05-18 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
ES2651296T3 (es) | 2009-10-30 | 2018-01-25 | Janssen Pharmaceutica, N.V. | Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10 |
WO2011078221A1 (ja) | 2009-12-24 | 2011-06-30 | 味の素株式会社 | イミダゾピリダジン化合物 |
CA2784769A1 (en) | 2010-01-15 | 2011-07-21 | Janssen Pharmaceuticals, Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
WO2011137155A1 (en) | 2010-04-28 | 2011-11-03 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
JP5926727B2 (ja) | 2010-07-28 | 2016-05-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換イミダゾ[1,2−b]ピリダジン |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
CN103328473A (zh) | 2010-11-12 | 2013-09-25 | 百时美施贵宝公司 | 取代的氮杂吲唑化合物 |
EP2651944B1 (en) | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
CA2821829A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
MX2013010970A (es) | 2011-03-24 | 2013-10-17 | Cellzome Ltd | Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa. |
GB201108003D0 (en) | 2011-05-13 | 2011-06-29 | Materialise Dental Nv | Endodontic treatment simulation system |
US20140288069A1 (en) | 2011-05-17 | 2014-09-25 | Bayer Intellectual Property Gmbh | Amino-substituted imidazopyridazines as mknk1 kinase inhibitors |
ES2625854T3 (es) | 2011-06-01 | 2017-07-20 | Bayer Intellectual Property Gmbh | Aminoimidazopiridazinas sustituidas |
ES2610366T3 (es) | 2011-06-22 | 2017-04-27 | Bayer Intellectual Property Gmbh | Heterociclil-aminoimidazopiridazinas |
WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
ES2555167T3 (es) | 2011-07-15 | 2015-12-29 | Janssen Pharmaceuticals, Inc. | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103814029B (zh) | 2011-09-23 | 2016-10-12 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
EP2760870B1 (en) | 2011-09-27 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
MX343561B (es) * | 2011-11-01 | 2016-11-09 | Hoffmann La Roche | Compuestos de imidazolpiridazina. |
CA2860547A1 (en) | 2012-01-10 | 2013-07-18 | Johannes Cornelius Hermann | Pyridazine amide compounds and their use as syk inhibitors |
MX347917B (es) * | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
JP6106745B2 (ja) | 2012-05-16 | 2017-04-05 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | (特に)アルツハイマー病の治療に有用な置換3,4−ジヒドロ−2H−ピリド[1,2−a]ピラジン−1,6−ジオン誘導体 |
EP2863909B1 (en) | 2012-06-26 | 2020-11-04 | Janssen Pharmaceutica N.V. | Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
CN104411314B (zh) | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | 磷酸二酯酶10的抑制剂 |
TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
WO2014039595A1 (en) * | 2012-09-06 | 2014-03-13 | Bristol-Myers Squibb Company | Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
EP2920181B1 (en) | 2012-11-16 | 2019-01-09 | University Health Network | Pyrazolopyrimidine compounds |
AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
US9475817B2 (en) | 2012-12-21 | 2016-10-25 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
US9556179B2 (en) | 2012-12-21 | 2017-01-31 | Bristol-Myers Squibb Company | Substituted imidazoles as casein kinase 1 D/E inhibitors |
WO2014111457A1 (en) | 2013-01-17 | 2014-07-24 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
WO2014200885A1 (en) | 2013-06-11 | 2014-12-18 | Janssen Pharmaceutica Nv | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES |
HUE033131T2 (en) | 2013-06-11 | 2017-11-28 | Bayer Pharma AG | Derivatives of substituted triazolopyridines |
WO2014200882A1 (en) | 2013-06-11 | 2014-12-18 | Janssen Pharmaceutica Nv | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES |
UY35625A (es) | 2013-06-25 | 2014-12-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa |
WO2014210087A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
JP6458038B2 (ja) * | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
EP3087069B1 (en) | 2013-12-23 | 2019-01-30 | Norgine B.V. | Compounds useful as ccr9 modulators |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
TW201613927A (en) | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
SG11201703188QA (en) | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Indole carboxamides compounds useful as kinase inhibitors |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
KR101635173B1 (ko) | 2014-12-03 | 2016-06-30 | 충남직물공업협동조합 | 디지털프린팅 날염 친환경 자카드직물의 제조방법 및 그 직물 |
MD3233862T2 (ro) | 2014-12-19 | 2019-11-30 | Janssen Pharmaceutica Nv | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta |
AU2015366202B2 (en) | 2014-12-19 | 2020-01-02 | Janssen Pharmaceutica Nv | Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors |
CA2978170C (en) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
PE20230731A1 (es) | 2015-12-22 | 2023-05-03 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
LT3458456T (lt) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
PE20190731A1 (es) | 2016-06-20 | 2019-05-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JP7012082B2 (ja) * | 2016-11-17 | 2022-01-27 | ブリストル-マイヤーズ スクイブ カンパニー | Il-12、il-23および/またはifn-アルファのイミダゾピリダジン調節剤 |
ES2952744T3 (es) | 2016-12-15 | 2023-11-03 | Nestle Sa | Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
RU2770363C2 (ru) | 2017-04-05 | 2022-04-15 | Куровир Аб | Гетероароматические соединения, пригодные в терапии |
WO2019169249A1 (en) * | 2018-03-01 | 2019-09-06 | The Johns Hopkins University | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
AU2019311117A1 (en) * | 2018-07-27 | 2021-02-04 | Cocrystal Pharma, Inc. | Pyrrolo(2,3-b)pyridin derivatives as inhibitors of influenza virus replication |
JP2022518505A (ja) * | 2019-01-23 | 2022-03-15 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
EP4268824A1 (en) * | 2022-04-26 | 2023-11-01 | Manros Therapeutics | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166851A (en) | 1977-05-16 | 1979-09-04 | Merck & Co., Inc. | Certain imidazo(1,2a)pyridine derivatives |
CH635587A5 (fr) * | 1978-01-09 | 1983-04-15 | Aron Sa | Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation. |
FR2619818B1 (fr) * | 1987-09-01 | 1990-01-12 | Sanofi Sa | Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
US5260285A (en) | 1990-12-07 | 1993-11-09 | Merck & Co., Inc. | Substituted imidazopyridazines as angiotensin II antagonists |
DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
CA2263566C (en) * | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
WO2002050079A1 (fr) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
FR2850653A1 (fr) * | 2003-02-04 | 2004-08-06 | Univ Pasteur | Derives de pyrazolotriazine, procede de preparation et utilisations |
EP1599482A4 (en) * | 2003-02-28 | 2008-10-01 | Teijin Pharma Ltd | PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES |
DE10356579A1 (de) * | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
PE20051128A1 (es) * | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
US7537840B2 (en) * | 2004-08-05 | 2009-05-26 | H.B. Licensing & Financing, Inc. | Polyamide adhesive and articles including the same |
EP1879896A1 (en) * | 2005-04-05 | 2008-01-23 | Eli Lilly And Company | Imidazopyridazine compounds |
-
2006
- 2006-09-21 US US11/524,996 patent/US20070078136A1/en not_active Abandoned
- 2006-09-22 GE GEAP200610649A patent/GEP20104943B/en unknown
- 2006-09-22 CA CA2623369A patent/CA2623369C/en active Active
- 2006-09-22 KR KR1020087009516A patent/KR101399766B1/ko active IP Right Grant
- 2006-09-22 DK DK06825074.5T patent/DK1928879T3/da active
- 2006-09-22 KR KR1020147007661A patent/KR20140058645A/ko not_active Application Discontinuation
- 2006-09-22 JP JP2008532430A patent/JP5241498B2/ja active Active
- 2006-09-22 TW TW102124973A patent/TWI478925B/zh active
- 2006-09-22 PE PE2006001149A patent/PE20070520A1/es active IP Right Grant
- 2006-09-22 SI SI200631578T patent/SI1928879T1/sl unknown
- 2006-09-22 EP EP06825074A patent/EP1928879B1/en active Active
- 2006-09-22 TW TW095135141A patent/TWI441825B/zh not_active IP Right Cessation
- 2006-09-22 WO PCT/US2006/037056 patent/WO2007038314A2/en active Application Filing
- 2006-09-22 EA EA200800873A patent/EA017632B1/ru not_active IP Right Cessation
- 2006-09-22 PL PL06825074T patent/PL1928879T3/pl unknown
- 2006-09-22 PT PT68250745T patent/PT1928879E/pt unknown
- 2006-09-22 AU AU2006295439A patent/AU2006295439B2/en not_active Ceased
- 2006-09-22 ES ES06825074T patent/ES2402664T3/es active Active
- 2006-09-22 BR BRPI0616393A patent/BRPI0616393B8/pt active IP Right Grant
- 2006-09-22 NZ NZ566663A patent/NZ566663A/en unknown
- 2006-09-25 AR ARP060104153A patent/AR055177A1/es active Pending
-
2008
- 2008-03-10 NO NO20081231A patent/NO20081231L/no not_active Application Discontinuation
- 2008-03-18 IL IL190280A patent/IL190280A/en active IP Right Grant
-
2013
- 2013-02-25 HR HRP20130155TT patent/HRP20130155T1/hr unknown
- 2013-05-09 CY CY20131100374T patent/CY1114001T1/el unknown
- 2013-06-21 PH PH12013501329A patent/PH12013501329A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130155T1 (hr) | Fuzionirani heterocikliäśki spojevi korisni kao modulatori kinaze | |
JP2009509961A5 (hr) | ||
US10604504B2 (en) | Indole carboxamide compounds | |
NZ592809A (en) | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | |
TW411335B (en) | Substituted diamino-1,3,5-triazine derivatives having HIV replication inhibiting activities | |
HRP20180037T1 (hr) | Heterociklični spoj koji sadrži dušik ili njegovu sol | |
RU2405780C2 (ru) | Химические соединения | |
JP2020183410A5 (hr) | ||
HRP20171638T1 (hr) | Derivati pirazolin diona kao inhibitori nadph oksidaze | |
JP2004511512A5 (hr) | ||
JP2002526501A5 (hr) | ||
JP2003535828A5 (hr) | ||
HRP20140807T1 (hr) | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b | |
CA2452217A1 (en) | Hiv inhibiting pyrimidines derivatives | |
JP2007500129A5 (hr) | ||
JP2014139226A5 (hr) | ||
RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
AU2015335703A1 (en) | Carbazole derivatives | |
JP2019527724A5 (hr) | ||
JP2022017461A5 (hr) | ||
JP2007513872A5 (hr) | ||
RU2007119776A (ru) | Новые аминопиридиновые производные, обладающие селективной aurora a ингибирующей активностью | |
JP2022541522A (ja) | Irak4阻害剤として有用な三環式ヘテロアリール化合物 | |
CA2487948A1 (en) | Azole methylidene cyanide derivatives and their use as protein kinase modulators | |
JPWO2021157650A5 (hr) |